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ABSTRACT 
 
Problem definition:  Malnutrition increases the incidence and exacerbates the clinical 
manifestations of TB.  Hepatotoxicity is one of the most serious and most frequent side-effects of 
anti-tuberculosis drugs and may be three times higher in malnourished patients. 
 
Objective:  The influence of nutritional and retroviral status on the bio-availability and toxicity of 
anti-tuberculosis agents was studied and a possible relationship between abdominal lymph node 
enlargement and the occurrence of malnutrition investigated. 
 
Subjects and setting:  The study subjects were 53 children, 19 HIV-infected and 34 HIV-
uninfected, aged 3 months to 13 years with probable or confirmed tuberculosis admitted to the 
paediatric ward of Brooklyn Hospital for Chest Diseases in Cape Town, South Africa.  The 
nutritional status of the children was assessed over the first four months of tuberculosis 
treatment by nutrient intake, anthropometric status and biochemical parameters.  The 
relationship between abdominal lymph node enlargement and the occurrence of malnutrition 
was also evaluated.  Pharmacokinetic studies were performed to evaluate the bio-availability of 
anti-tuberculosis agents and drug hepato-toxicity was evaluated by liver function. 
 
Results:  Stunting (46.27%) and underweight (34.51%) were the most common types of 
malnutrition in the children studied.  HIV-infection did not have a significant effect on stunting or 
wasting, but had a significant effect (p=0.003) on underweight for age with 31.5% HIV-infected 
compared to 2.9% HIV-uninfected at enrolment, but the effect was not statistically significant at 
month 4.  There was no change in the number of stunted, wasted or underweight children from 
enrolment after 1 month of treatment to month 4 of treatment. 
 
HIV-infection did not have a significant effect on abdominal TB involvement (p=0.43354), and 
nutritional status was not significantly affected by abdominal lymph-node involvement. 
 
At enrolment weight for age had a significant effect on AST and ALT with p-values of 0.02166 
and 0.02765 respectively and wasting had a significant effect on GGT at enrolment (p=0.03014).  
However on enrolment only two HIV-infected and two HIV-uninfected children had ALT values 
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increased >X2 normal.  Similarly AST values >X3 normal were found in only one HIV-infected 
child and two HIV-uninfected children.  Stunting did not significantly affect liver enzymes.  
Anthopometric status did not have a significant effect on liver enzymes at month 4. 
 
None of the parameters used to determine nutritional status had a statistically significant effect 
on INH-levels or RMP-levels. 
 
HIV-infection had a significant negatve effect on selenium (p=0.030 and 0.012) and ferritin 
(p=0.026 and 0.002) at enrolment and month 4 and on IBC (p=0.025) at enrolment.  At month 4 
HIV-infection had a significant negative effect on the mean vitamin C-levels (p=0.005). 
 
Conclusions:  HIV co-infection did not affect the extent or distribution of body composition 
changes in this study.  Stunting was the most prevalent form of malnutrition in the study group, 
indicating longstanding undernutrition, which may be due to factors other than the present TB 
infection.  Appropriate treatment of tuberculosis did not appear to affect the nutritional status 
over the four month period of the study. 
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OPSOMMING 
 
Probleemstelling:  Wanvoeding verhoog die insidensie en vererger die kliniese beeld van TB.  
Hepatotoksisiteit is een van die ernstigste en algemeenste newe-effekte van anti-tuberkulose 
middels en mag tot drie keer hoër wees in wangevoede pasiënte. 
 
Doelwit:  Die invloed van die kinders se voedings- en retrovirale status op die bio-
beskikbaarheid en toksisiteit van anti-tuberkulose middels was ondersoek en „n moontlike 
verband tussen vergrote abdominale limfnodes en die voorkoms van wanvoeding was 
ondersoek. 
 
Deelnemers en omgewing:  Die deelnemers aan die studie was 53 kinders, 19 HIV-positief en 
34 HIV-negatief, tussen die ouderdomme van 3 maande en 13 jaar met moontlike of bevestigde 
tuberkulose toegelaat tot die pediatriese saal van Brooklyn Hospitaal vir Borskwale in Kaapstad, 
Suid Afrika.  Die voedingstatus van die kinders was bepaal oor die eerste vier maande van 
tuberkulose behandeling ten opsigte van nutriëntinname, antropometriese status en 
biochemiese parameters.  Die verhouding tussen vergrootte abdominale limfnodes en die 
voorkoms van wanvoeding was ook geëvalueer.  Farmakokinetiese studies was uitgevoer om 
die bio-beskikbaarheid van anti-tuberkulose middels te evalueer en hepatotoksisiteit was deur 
lewerfunksie geëvalueer. 
 
Resultate:  Dwerggroei (46.27%) en ondergewig (34.51%) was die algemeenste tipes 
wanvoeding teenwoordig by die kinders bestudeer.  HIV-infeksie het nie „n noemenswaardige 
effek op dwerggroei of uittering gehad nie, maar het wel „n noemenswaardige effek (p=0.003) 
getoon op ondergewig vir ouderdom met 31.5% HIV-positief vergeleke met 2.9% HIV-negatief 
by inskrywing, wat nie statisties noemenswaardig was teen maand 4 nie.  Daar was geen 
verandering in die hoeveelheid kinders met dwerggroei, uittering of ondergewig vanaf inskrywing 
na 1 maand van behandeling tot maand 4 van behandeling nie. 
 
HIV-infeksie het nie 'n noemenswaardige effek op abdominale TB gehad nie (p=0.43354), en 
vergrootte abdominale limfnodes het nie „n noemenswaardige effek op voedingstatus gehad nie. 
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By inskrywing het gewig vir ouderdom „n noemenswaardige effek op AST en ALT gehad met p-
waardes van 0.02166 en 0.02765 onderskeidelik en uittering het „n noemenswaardige effek op 
GGT by inskrywing gehad (p=0.03014).  Dwerggroei het nie die lewerensieme noemenswaardig 
beïnvloed nie.  Antropometriese status het nie „n noemenswaardige effek op lewerensieme teen 
maand 4 gehad nie. 
 
Geen van die parameters wat gebruik is om voedingstatus te bepaal het „n noemenswaardige 
statistiese effek op INH-vlakke of RMP-vlakke gehad nie. 
 
HIV-infeksie het „n noemenswaardige effek op selenium (p=0.030 en 0.012) en ferritien (p=0.026 
en 0.002) by inskrywing en maand 4 gehad en op IBC (p=0.025) by inskrywing.  HIV-infeksie het 
„n statisties noemenswaardige effek op die gemiddelde vitamien C-vlakke (p=0.005). 
 
Gevolgtrekking:  HIV ko-infeksie het nie die verspreiding of mate van liggaamsamestelling 
veranderinge in hierdie studie geaffekteer nie.  Dwerggroei was die algemeenste vorm van 
wanvoeding in die studiegroep, wat langstaande wanvoeding aandui en toegeskryf mag word 
aan faktore buiten die huidige TB infeksie.  Toepaslike tuberkulose behandeling het nie „n 
wesenlike effek op voedingstatus gehad tydens die vier maande periode van die studie nie. 
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CHAPTER 1:  INTRODUCTION AND MOTIVATION OF THE STUDY 
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1.1 Introduction 
Tuberculosis (TB) is the most common cause of infection-related deaths worldwide and is the 
most common opportunistic infection to develop in human immunodeficiency virus (HIV)-infected 
children and adults.  This interaction has a negative effect on the prognosis of both diseases and 
has been called the “cursed duet”.1 
 
Africa, home to 11% of the world‟s population, has 29% of the global number of TB cases.  The 
World Health Organisation (WHO) estimates that the incidence of TB in Africa more than 
doubled between 1990 and 2006, from 149 to 334 per 100 000 population per year in contrast 
with the stable or declining rates in all other regions during this period.2,3  HIV/AIDS is 
responsible for most of the recent increase in TB incidence in Africa.  Co-infection with HIV 
greatly increases the risk of latent TB will develop into active disease.2,4  Table 1.1 shows the 
estimated prevalence and incidence of TB globally and compared to South Africa.  From these 
figures it is clear why TB has been called a time-bomb in Africa.5 
 
Table 1.1 Estimated global TB cases 
 Global South Africa SA ranking 
world wide 
TB prevalence rate (people living with TB) 
per 100 000 population 
219 998 Third highest 
New TB cases per 100 000 population 139 940 Second highest 
TB in HIV positive people per 100 000 
population 
11 416 Second highest 
HIV prevalence in incident TB cases 8% 44% Sixth highest 
Source: Data from Global Health Facts6 
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Risk factors for the development of active TB disease include HIV-infection, sharing a home with 
someone who has active TB, malnutrition, poverty and impaired immune function.4  Children are 
usually infected with TB by a smear-positive family member or other close contact.  Therefore, 
the most effective way to prevent childhood TB is early identification and proper treatment of 
infectious adult cases.3  Children may present with active TB at any age, but disease is most 
common between one and four years, most probably due to an underdeveloped immune 
response.7  Although the short-term response to treatment in HIV-infected and non-HIV-infected 
TB patients is usually considered similar, the mortality during therapy is considerably higher in 
both children8,9,10 and adults who are HIV-infected.11,12,13 
 
HIV-infection impairs cell-mediated immunity, increasing the risk of TB infection and the 
reactivation of latent TB in adults and children.3  The development of active TB disease is the 
first sign of AIDS in many HIV-infected individuals.  Active TB disease often occurs at higher 
CD4 lymphocyte counts than other HIV-related illnesses.  Active TB often decreases the number 
of CD4 lymphocytes which increases HIV viral replication.  Both diseases therefore accelerate 
the progress of the other.2,7 
 
The latest UNAIDS data shows global HIV prevalence has leveled off and that the number of 
new infections have been reduced, in part as a result of the impact of HIV programs.  
Nonetheless, in 2007 33.2 million people were estimated to be living with HIV, of which 2 million 
are children under 15 years of age.  In the same year 2.7 million people became newly infected, 
including 370 000 children under the age of 15 years and 2 million people (270 000 children) 
died of acquired immunodeficiency syndrome (AIDS).14 
 
Southern Africa carries a disproportionate share of the global burden of HIV, 35% of new HIV 
infections and 38% of AIDS deaths in 2007.  Sub-Saharan Africa remains the most severely 
affected as 68% of the global total and almost 90% of infected children live in Sub-Saharan 
Africa.  In Table 1.2 the prevalence of HIV-infection in South Africa is compared with global 
rates.14 
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Table 1.2 Estimated HIV-infection rates (2007) 
 Global Sub-Saharan Africa South Africa 
Estimated number of people 
(all ages) living with HIV 
33 million 
(30 – 36 million) 
22 million 
(20.5 – 23.6 million) 
5.7 million 
(4.9 – 6.6 million) 
Estimated number of children 
(0-14 years) living with HIV 
2 million 1.8 million 280 000 
Estimated adult (15-49 years) 
HIV prevalence rate 
0.8% 5% 18.1% 
Children (0-17 years) 
orphaned by AIDS 
15 million 11.6 million 1.4 million 
Source: Data from UNAIDS14 
 
World-wide approximately one third of people living with HIV are co-infected with TB1, while 50% 
of all HIV-infected patients in South Africa have TB.15  TB kills more HIV-infected people in Africa 
than any other AIDS-related disease.  Among HIV-infected children, TB accounts for up to one in 
five of all deaths.15 
 
Malnutrition raises the incidence and exacerbates the clinical manifestations of TB.16  Nutritional 
status is one of the most important determinants of resistance to infection.2,17,18,19  Undernutrition 
is implicated in up to 50% of all deaths in children under 5.  Table 1.3 shows the percentage of 
malnourished children younger than 5 years of age, globally and in South Africa.  The South 
African numbers are estimated by UNICEF and might not be a true reflection of the extent of 
malnutrition in South Africa.20 
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Table 1.3 Percentage of under-fives malnourished (2000-2006) 
  Global Sub-Saharan 
Africa 
South Africa 
Underweight 
(NCHS/WHO) 
Moderate and 
severe 
25 28 12 
 Severe - 8 2 
Wasted 
(NCHS/WHO) 
Moderate and 
severe 
11 9 3 
Stunted 
(NCHS/WHO) 
Moderate and 
severe 
28 38 25 
Source: Data from UNICEF20 
 
1.2 Nutritional Status and Immunity 
The human body (host) has an ability to distinguish between self and non-self substances or 
organisms.  Working together, a multi-level system of cells and biochemical factors recognize, 
attack and destroy the foreign substance.  Components of immune responses may be 
categorised as non-specific and specific responses, as illustrated in Figure 1.1.21,22 
 
Antigen non-specific responses do not require recognition of a particular antigen and include the 
mucous membrane and phagocytes.  The mucous secretions of the mucous membrane contain 
a variety of biochemical and immunological factors that attack bacterial cell walls, starting the 
process leading to the destruction of bacteria.  Phagocytes (granulocytes and macrophages) 
move to the area of foreign invasion and participate directly in intracellular killing of bacteria and 
viruses.  Macrophages and their secretory products directly and indirectly stimulate components 
of the immune response, as well as B- and T-cell functions.  Part of the stimulation process is 
the production of lymphokines, e.g. interferons and interleukin-1.  Interferons stimulate cell 
replication and differentiation and are active in stimulating T-cell functions. Interleukin-1 
stimulates the hypothalamus to induce fever and heighten the rate of body metabolism to fight 
infection.21,22,23 
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An antigen specific response requires the recognition of foreign antigens, is specific in its 
interaction with the antigen and has memory of past antigenic exposure.  Antigen specific 
responses include antibodies and cell-mediated immunity.  Antibodies are immunoglobulins 
produced by mature B-lymphocytes.  Large amounts of antibodies are produced to complex 
specifically with the antigen.  Cell-mediated immunity consists of T-lymphocytes.  The antigen is 
attacked for direct killing of the invading organism.  Activation of antigen specific complement 
promotes phacocytosis, viral neutralization and lysis of virus infected cells after bacterial 
removal.7,21,22,23 
 
 
Figure 1.1: The specific and non-specific components of the immune response 
 
STIMULUS
Bacteria
Virus
Chemical
Particulate
Immune response activated
Non specific
Mucosal
Phagocytosis
Inflammation
Specific
Humoral
Cell-mediated
Removal of stimulus
Feedback regulation of immune response
Memory
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Malnutrition limits cell-mediated and humoral immunity and increases susceptibility to 
infection.24,25  Infection can lead to nutritional stress and weight loss, resulting in a weakened 
immune function and nutritional status.7 
 
 
 
 
 
 
 
Figure 1.2: The malnutrition-infection cycle 
 
The immune response is a rapidly acting system with cells and secretory products having 
relatively short life spans, therefore nutrient functions have dramatic effects on the 
responsiveness of the system.  The severity of the impairment of immunity depends upon the 
severity of nutrient deficiency. (Figure 1.2)  Isolated deficiencies are rare, with the exception of 
iron, vitamin A and zinc, but they frequently complicate malnutrition.7,23 
 
Nutrients are involved in different ways in the immune response, including the anatomical 
development of lymphoid tissue, mucous production, synthesis of immunologically active 
proteins, cell proliferation and regulation of immune processes.26  Table 1.4 summarises the 
nutrients involved in different immune functions. 
Malnutrition
↓Cellular immunity ↓Humoral immunity
Infection
Catabolic state
Negative nitrogen balance
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Table 1.4: Nutrients affecting immune function 
Immune function Nutrients involved 
Non specific immune response  
Mucosal 
 Lysozymes 
Protein-energy malnutrition (PEM) 
Vitamin A 
Phagocytes 
 Macrophages 
 Granulocytes 
Iron deficiency 
Vitamin C  
Fatty acids 
Specific immune response  
Humoral 
 B-lymphocytes 
 
Iron 
Vitamin A 
Vitamin E  
Vitamin B6  
Essential fatty acids 
Cell mediated 
 T-lymphocytes 
 
Vitamin A  
Vitamin B12 
Zinc 
Folic acid 
Poly unsaturated fatty acids 
 
In protein energy malnutrition in children the thymus becomes atrophied resulting in decreased 
T-lymphocytes in circulation.  The total number of circulating B-cells and serum immunoglobulin 
concentrations are also reduced.  Total energy restriction alone does not seem to be nearly as 
devastating to t-cell functions as protein deficiency.  A delayed chemotaxic movement of 
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neutrophils toward the stimulus and defective microbicidal activity and impaired release of 
lysosomal enzymes is also seen in malnutrition.26,27 
  
The interrelationship between infection, nutritional status and immune function are especially 
apparent in individuals with HIV, who have impaired immune function and altered nutritional 
status.23,24,28  Immune defence at the epithelial barrier of the undernourished host is impaired 
due to altered structure of the gut mucosa, such as flattened hypotrophic microvilli, reduced 
lymphocyte counts in Peyer‟s patches, and reduced immunoglobulin A (IgA) secretion.  
Malnutrition reduces the availability of complement components, thereby affecting the capacity 
of phagocytes to eliminate pathogens.21,24,26 
 
1.3 Effect of Malnutrition on TB and HIV 
TB infection occurs when individuals inhale the aerosolized tubercle bacilli.  Alveolar 
macrophages phagocytose the inhaled bacilli.  The macrophages are unable to kill the 
mycobacteria and the bacilli continue to multiply.  A cell-mediated response terminates the 
growth of Mycobacteria tuberculosis 2-3 weeks after infection.  However, the initial pulmonary 
site of infection (the primary focus or Ghon focus) and its adjacent lymph nodes (together the 
primary complex or Ghon complex) sometimes enlarge and develop necrosis and calcification. 
 
Malnutrition is an important risk factor for TB, because cell-mediated immunity is the main host 
defense against TB.29,30  Individuals with immuno-suppression or malnutrition have a greater risk 
of TB, since infection is more likely to progress to active TB when the cell mediated immune-
response is impaired, as observed in people with HIV infection.31  The HIV epidemic continues to 
have a major impact on child health and survival worldwide.  Seventy five percent of all infected 
children die before the age of five years.14 
 
Body weight consists of fat free mass (muscle tissue) and fat mass.  Patients with active TB 
generally have lower body mass index (BMI), skinfold thicknesses, mid-upper arm circumference 
(MUAC) and proportion of fat than healthy adults.32  Wasting in TB is associated with overall 
depletion of lean and fat tissue in approximately equal proportions, but lean tissue depletion is 
greater in the limbs and fat tissue depletion greater in the trunk in adults.32,33  HIV co-infection 
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does not affect the extent or distribution of the body composition changes33, suggesting that TB 
(rather than HIV) is the dominant factor driving the wasting in patients with co-infection.  
Published data of anthropometric studies in children with TB and HIV and the response to 
treatment are scarce, rather focusing on adults with co-infection. 
 
Weight loss and malnutrition frequently occurs in the later stages of HIV-infection and both 
patients with AIDS and protein energy malnutrition (PEM) will experience infections of mycotic, 
parasitic and bacterial origin.34  Nutritional complications develop as the disease progresses and 
signs and symptoms of HIV-infection manifest.  Malabsorption and diarrhea are the most 
important nutritional problems encountered in advanced AIDS35,36 and are caused by a relatively 
high cell turnover rate of the mucosal tissue of the gastrointestinal tract.37  This impairs the 
absorption of several essential nutrients and promotes intestinal infections and diarrhoea.35,38  
Patients with intestinal infection of the small bowel commonly have malabsorption of fat, mono- 
and disaccharides, nitrogen, vitamin B12, folate, minerals and trace elements.
39  Fat 
malabsorption frequently occurs in AIDS patients and is not always accompanied by diarrhoea. 
 
Severe weight loss as seen in PEM may cause organ damage, which increases the risk of a 
fatal outcome from infections.1,40  Myocardial cells in the heart show histological changes and 
the cardiac reserve decreases, atrophy of the digestive system and bacterial overgrowth is 
common.  The exocrine function of the pancreas is impaired and fatty infiltration of the liver takes 
place.  Brain atrophy, causing intellectual and emotional disturbances may also occur.21  Body 
cell mass, the amount of functional protoplasm in non-adipose tissue, may be the best predictor 
of death.41  Metabolic (endocrine) abnormalities common in PEM, such as decreased levels of 
insulin and somatomedines causes a slowing down of growth and decreased levels of cortisol 
triggers an increased amino-acid release.  This contributes to the depletion of lean tissue with 
little loss of fat36,42, in contrast with starvation, where fat stores are depleted.40 
 
1.4 Micronutrient Malnutrition 
Micronutrients are important for the functioning of the immune response.  Vitamin A is needed 
for the maintenance of healthy epithelial tissue (mucosal immunity) and antibody production 
(humoral immunity).43  The active metabolite of vitamin D, calcitriol, has an effect on the 
synthesis of immunoregulatory molecules, namely macrophages and lymphocytes.44  Iron 
  11 
deficiency causes a reduction in interleukin-1 production (phagocytosis).  On the other hand iron 
is needed by most bacteria for growth and multiplication.  Clinical data does not support the 
suggestion that iron deficiency protects against infection.45  Vitamin C plays a role in the 
mobilization and aggregation of macrophages.  Low levels of vitamin B12, zinc vitamin A and folic 
acid result in impaired T-cell proliferative responsiveness.46 
 
Micronutrient deficiencies have been described in individuals with HIV infection47 and in those 
with TB32,48, resulting from poor nutrition as well as the diseases itself.  It has been found that 
patients with tuberculosis, as well as patients with HIV are prone to developing deficiencies of 
vitamin A, vitamin B6, folate, vitamin C, vitamin E, zinc, selenium and thiamin.
45,49,50  Deficiencies 
of vitamin B12 and vitamin C are also more prevalent among HIV-infected adults than in HIV-
uninfected adults.50 
 
Although zinc plays a fundamental role in immunity, the safety of zinc supplementation in HIV-
infected adults is controversial, as higher dietary intake of zinc appear to be related to decreased 
survival.45 
 
1.5 Metabolism and Toxicity of Antituberculosis Agents 
For drugs to have the intended disease altering effect, they have to go through several phases.  
First is the pharmacokinetics, that is the movement of the agent.  After the administration 
absorption, distribution, metabolism and excretion takes place.  Part two is the 
pharmacodynamic (the action of the drug) part.  This includes binding to receptors, inhibiting 
enzymes or changing of cell membrane function. 
 
There are a number of pharmacokinetic aberrations in malnutrition which are related to hepatic 
and renal dysfunction and changes in plasma protein binding.  The liver is the main drug 
metabolizing organ and is anatomically and functionally deranged in PEM.51,52 
 
Drugs are bound to plasma proteins to be distributed through the body.  This binding is 
reversible and only free agent can move over capillary membranes.  It has been found that an 
altered serum protein pattern (decreased albumin, increased total protein) in often seen in AIDS 
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patients.53  As rifampicin is relatively highly protein –bound (up to 80%)54 this altered protein 
pattern  may affect rifampicin to a larger extent than isoniazid or pyrazinamide.53  If plasma 
protein binding is decreased the free drug concentration is increased.  The therapeutic effect 
may not be enhanced since, being free, the drug may be eliminated more rapidly.55 
 
In patients co-infected with HIV and TB altered pharmacokinetic profiles for anti-mycobacterial 
drugs are described.56  AIDS may predispose patients to malabsorption of antimycobacterial 
drugs due to its gastrointestinal associations such as opportunistic bowel infections, gastric 
hypoacidity and enteropathy, thus affecting the efficacy of treatment.57 
 
Isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA) are the three main drugs used to treat 
tuberculosis.58  Hepatotoxicity is one of the most serious and most frequent side-effects of these 
drugs.  The severity ranges from alteration in liver enzymes, chronic active hepatitis and acute 
hepatitis, occasionally complicated by acute liver failure with high mortality unless transplanted.59 
 
The most widely accepted risk factors for hepatotoxocity in patients treated with anitituberculosis 
drugs are old age, previous history of chronic liver disease, chronic alcoholism, elevated serum 
transaminases prior to treatment, concomitant use of certain other drugs and poor nutritional 
status.60  Anti-tuberculosis therapy inducible cytochrome P-450 2 E1 (cyp2E1) is expressed in 
the liver.  Recent studies61,62 have shown that polymorphism of the N-acetyltranferase2 (NAT2) 
genes and glutathione-s transferases (GST) are the main susceptibility risk factors for anti-
tuberculosis therapy induced hepatotoxicity.61  Antituberculosis therapy induced hepatotoxicity in 
malnutrition may be explained by a depletion of glutathione stores, which results in increased 
vulnerability to oxidative injuries.62  It has been shown that the incidence of antituberculosis 
therapy induced hepatotoxicity may be three times higher in malnourished patients.63 
 
Peripheral neuropathy is a known adverse effect associated with antituberculosis therapy.  INH 
causes sensory and motor neuropathy, with an estimated incidence of 0.2%, although at higher 
doses the incidence has been reported to be as high as 40%.64,65  Old age, alcoholism, 
malnutrition, pregnancy, as well as renal or hepatic dysfunction are risk factors for the 
development of INH-associated neuropathy.66  Co-administration of pyridoxine is protective, 
although excessive amounts may cause peripheral neuropathy.67 
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1.6 Bio-availability of Anti-tuberculosis Agents 
Bio-availability measures the relative amount of an administered drug in the circulation (Cp), 
against a standard reference over time.  Parameters include the time needed to reach maximum 
serum concentration (t max) and maximum concentration for a given dose (C max).53,68  It has 
been found that HIV-infection causes malabsorption of first line anti-TB drugs even at an early 
stage of the disease.  HIV-infected persons have increased intestinal permeability and a 
significant correlation exists between malabsorption and degree of immunosuppression.52,69 
 
RMP INH and PZAare absorbed from the proximal gastro-intestinal tract.  Although 
malabsorption is common in patients with intestinal TB it does not impair blood levels of these 
drugs.70 
 
The metabolizing enzyme of INH is a hepatic N-acetyl transferase, which displayes genetic 
polymorphism.  This enzyme has two phenotypes, slow and rapid acetylators of INH.  The rapid 
acetylators have four to five times more of the enzyme than slow acetylators.  Rapid acetylators 
therefore have enhanced metabolism of INH causing lower blood levels and urinary excretion 
than slow acetylators.69 
 
1.7 Abdominal Lymph Node Involvement 
A significant number of children with TB will also have involvement of the abdominal 
lymphnodes.  The lymphatic drainage of the intestinal tract may be compromised due to 
obstruction, which leads to bacterial overgrowth in the gut, a variant of stagnant loop syndrome.  
This contributes to the development of malnutrition by malabsorption and loss of nutrients.  In 
the small intestine the ileum is more commonly involved than the jejunum.  This is attributed to 
the abundance of lymphoid tissue (Peyer patches) in the distal and terminal ileum.71  The result 
will be sub-optimal absorption of fat, fat-soluble vitamins, protein, carbohydrate, electrolytes and 
minerals.72 
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1.8 Motivation for the Study 
 
Limited information is available describing the pharmacokinetics of anti-TB drugs in children and 
the possible influence of HIV infection and nutritional status thereupon, although it is well 
described in adult TB patients. 
This study is nested in a primary study, sponsored by Bristol-Myers Squibb (BMS), examining 
the duration of treatment for TB and the pharmacokinetics and toxicity of anti-TB agents and 
other co-administered drugs in children, with and without HIV-infection and the relationship to 
the the NAT2 acetylator genotype and phenotype. 
The nutritional status of a group of children admitted to a TB referral hospital with severe forms 
of childhood TB is described.  The influence of the children‟s nutritional status on the absorption, 
metabolism and toxicity of anti-TB agents was examined.  The relationship between abdominal 
lymph node enlargement and the occurrence of malnutrition was also evaluated. 
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CHAPTER 2:  METHODOLOGY 
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2.1 Aim 
The aim of the study was to evaluate the influence of nutritional status of children aged 3 months 
to 13 years who were infected with TB, with or without HIV on the pharmacologic action and bio-
availibility of anti-TB agents. 
 
2.2 Objectives 
The specific objectives were to: 
1. Evaluate the nutritional status of the subjects at enrolment, and compare their 
anthropometric status at enrolment with anthropometric status after 4 months of anti-TB 
treatment and receiving a balanced diet in the hospital setting 
 
2. Investigate the influence of the children‟s anthropologic status, on the absorption, 
metabolism, bio-availability and toxicity of anti-TB agents 
 
3. Determine whether there was a relationship between abdominal lymph node 
enlargement and the occurrence of malnutrition 
 
2.3 Study Design 
The study used a prospective cohort design with a descriptive and analytical component.  
Convenience sampling was employed by selecting consecutive patients meeting the inclusion 
criteria on referral to Brooklyn Hospital for Chest Diseases (BHCD). 
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2.3.1 Inclusion criteria 
The inclusion criteria were: 
 Children between the ages of 3 months and thirteen years 
 Children with probable or confirmed tuberculosis admitted to BHCD 
 Written informed consent given by a parent or legal guardian for participation in the study 
and for HIV testing if the child‟s status was not known 
 Children less than one month on anti-tuberculosis treatment 
 
2.3.2 Study site 
BHCD is the non-acute TB hospital for the metropolitan area of the City of Cape Town.  BHCD 
admits complicated cases of tuberculosis and patients who are unable to receive community 
treatment.  Poor socio-economic status resulting in lack of transportation to clinics and inability 
of children‟s caregivers to accompany them to clinics are some of the main reasons why patients 
cannot receive effective community-based treatment. 
 
BHCD has 60 children‟s beds and has approximately 140 paediatric admissions annually.  
Children enrolled in this study were drawn from those admitted to BHCD.  As BHCD is not 
equipped for the management of more serious complications of TB or HIV/AIDS, it was 
necessary, at times, to transfer children to other secondary or tertiary hospitals. 
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2.3.3 Subjects 
Of the 420 children in BHCD during the period January 2004 to December 2006 (the duration of 
the study), 68 children were eligible for enrolment.  Consent was refused for 1 patient to be 
enrolled and consent could not be obtained for 7 children, because they did not have parents or 
legal guardians.  Sixty children, 26 HIV-infected and 34 HIV-uninfected were enrolled in the 
study.  Two groups of children were studied, the one with TB complicated by HIV/AIDS, and the 
other without HIV/AIDS.  Four children (all HIV-infected) were transferred back to referring 
hospitals shortly after enrolment due to complications that could not be handled at BHCD 
[Streptococcal pneumonia infection (N=1), gastro-enteritis and dehydration due to salmonella 
infection (N=1) and thrombocytopenia and surgical draining of the hip (N=1)] and three children 
were discharged from hospital after completion of the first pharmacokinetic study.  As a result 
these seven children were excluded from the study and their data not included in the analysis. 
The children were followed-up for four months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Subjects screened and enrolled in the study 
 
420 Paediatric patients was admitted to BHCD and screened during the study period
68 Patients met the inclusion criteria
Consent was obtained from 60 patients 8 Patients was excluded:
•1 refused consent
•7 patients did not have a parent or legal guardian to give
consent
Of 60 patients enrolled, 7 dropped out as follows:
•3 was discharged from hospital after enrolment 
•Blood could not be obtained from 1 patient
•3 patients was transferred to referring hospitals with complications:
Streptococcal pneumonia (N=1)
Gastro-enteritis and dehydration due to salmonella (N=1)
Thrombocytopenia and surgical draining of the hip (N=1)
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2.3.4 Diagnosis of TB 
A diagnosis of probable tuberculosis was made when two or more of the following clinical criteria 
were met: 
1(a) A Mantoux test giving an induration of ≥10mm in non-HIV infected children and ≥5mm in 
HIV-infected children.  Mantoux testing was done with tuberculin RT23 and the induration was 
measured in the transverse diameter of the forearm after 48-72 hours 
1(b) A history of close household contact within the last year of cases with sputum 
microscopy smear-positive pulmonary TB 
2 A chest x-ray suggestive of pulmonary TB 
3 A diagnosis of tuberculous meningitis (TBM) confirmed by a cranial computerized 
tomogram showing hydrocephalus and basal enhancement accompanied by appropriate 
cerebrospinal fluid changes, or other extra-thoracic disease manifestation highly 
suggestive of TB 
 
The diagnosis of tuberculosis was confirmed by a culture of M. tuberculosis from gastric 
aspirate, or sputum in older children, together with culture of cerebrospinal fluid in cases of TBM.  
The referring hospitals usually carried out these investigations before admission to BHCD. 
 
2.3.5 Treatment 
All forms of TB were treated with fixed dose combinations formulated for pediatric use.  During 
the intensive phase the fixed dose combination used was Rimcure®, containing 60mg rifampin, 
30mg INH and 150mg pyrazinamide.  Rimactizide® containing 60mg rifampin and 30mg INH 
was used during the continuation phase.  When the use of four drugs was advised, ethambutol 
was added during the intensive phase.  TBM was managed with the same fixed dose 
combination, but with added ethionamide given for six months and using higher dosages. 
 
All the children received a multivitamin supplement, supplying pyridoxine 0.5mg in the case of 
children 0-4 years of age and 1mg for those older than 5 years.  Each 5ml of this supplement 
contained 2.300IU vitamin A, 200IU vitamin D, 1mg vitamin B1, 1.2mg Vitamin B2, 5mg 
nicotinamide, 35mg vitamin C and 0.0025mg viamin B12. 
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Highly active anti-retroviral therapy (HAART) consisted of two necleoside reverse transcriptase 
inhibitors and ritonavir in children under 3 years of age, and ritonavir was replaced by efavirenz 
in children older than 3 years. 
 
2.3.6 Anthropometric measurements 
Anthropometric measurements were taken at enrolment and monthly after the start of anti-TB 
treatment for four months.  Data at enrolment and four months after the start of TB treatment 
was used to be able to make comparisons to the pharmacokinetic data.  Standard NCHS/WHO 
procedures developed for various age groups were used to measure body weight, height and 
mid-upper arm circumference (MUAC).59,60  Anthropometric measurements were taken by the 
researcher, a registered dietician. 
 
2.3.6.1 Weight 
The scale was calibrated to zero before weighing.  Children who could not stand independently 
(usually those under 24 months) was weighed on an pan-type pediatric electronic scale.  Infants 
were weighed nude and the reading taken to the nearest gram. 
 
Children who could stand independently were weighed on a platform balance beam scale, 
wearing only minimum clothing (underpants).  The child stood still in the middle of the platform 
without touching anything, while the reading was taken to the nearest 0.1kg.  The reading was 
taken three times and an average of the three readings recorded. 
 
2.3.6.2 Length (recumbent length) 
Recumbent length was measured for infants and children younger than 24 months of age.  A 
measuring device with a stationary headboard and movable footboard perpendicular to the 
backboard was used.  A registered nurse assisted with the measurements. 
 
In the supine position, the child‟s head was held against the backboard with the crown securely 
against the headboard and with the Frankfort plane perpendicular to the backboard.  The child‟s 
shoulders and buttocks were securely touching the backboard while keeping the legs straight 
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against the backboard.  The footboard was then placed against the bottom of the feet with the 
toes pointing upward.  The measurement was read to the nearest 0.1cm.  If the child could not 
be kept still the measurement was taken on the left leg. 
 
2.3.6.3 Height 
Children who could stand independently (older than 24 months) were measured in a standing 
position with a stadiometer.  The child stood barefoot with head in the Frankfurt horizontal plane, 
feet together, knees straight, arms hanging loosely at the sides, shoulders relaxed and head, 
shoulder blades, buttocks and heels touching the vertical surface of the stadiometer.  The 
headboard was lowered with enough pressure to compress the hair.  The child‟s height was 
measured three times and the average of the measurements was recorded to the nearest 
0.1cm. 
 
2.3.6.4 Mid-upper arm circumference (MUAC) 
The right arm of the child was measured along the horizontal line on the level of the mid-point of 
the upper arm.  The mid-point was located by bending the right arm at a 90 degree angle, palm 
facing upwards and the marking the mid-point of the distance between the acromion process 
and the tip of the olecranon.  Care was taken not to compress the soft tissue when taking the 
measurement with a measuring tape around the marked mid-point of the arm.  Measurements 
was taken to the nearest millimetre. 
 
2.3.6.5 Skinfolds 
A Lange caliper was used to take measurements.  The measurements were taken on the right 
side of the body.  The site where the measurements were taken was measured and marked 
before a reading being taken. 
 
The skinfold was firmly grasped by the thumb and index finger of the left hand 1cm proximal to 
the skin fold site and pulled away from the body.  The amount of tissue grasped was enough to 
form a fold with parallel sides.  The caliper was held in the right hand, perpendicular to the long 
axis of the skinfold and with the caliper‟s dial facing up for easy readability.  The caliper tips were 
placed on the site, about 1cm distal to the fingers holding the skinfold, so that pressure from the 
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fingers would not affect the measured value.  The dial was read approximately 4 seconds after 
the pressure from the measurer‟s hand has been released on the lever arm of the caliper.  Two 
measurements were taken at each site and if they differed a third was taken.  Readings were 
recorded to the nearest 0.5mm.  Pressure was maintained with the thumb and index finger 
throughout each measurement. 
 
 Triceps: 
The skinfold was measured parallel with the long axis of the arm, at the mid-point between the 
acromion process and point of the olecranon, with the arm hanging relaxed at the child‟s side.  
The elbow was flexed 90 degrees with the palm facing upwards to determine this mid-point. 
 
 Subscapular: 
The skinfold was measured 1cm below the lowest angle of the scapula, while the child was 
standing.  The long axis of the skinfold was on a 45 degree angle directed down and to the right 
side. 
 
 Arm muscle area (AMA) 
AMA is the bone-free muscle area and a good indication of lean body mass and an individual‟s 
skeletal protein reserves.  It is important in growing children and valuable in evaluating possible 
PEM.21  The assumption is made that triceps skinfold (TSF) and subscapular skinfold (SSF) 
measurements indicate energy reserves stored as fat and arm muscle area (AMA) reflect 
reserves stored as muscle protein.  The formula used to determine AMA is: 
AMA (cm²) = [MUAC-(π X TSF)]² / 4π 
Values were compared with percentiles from the United States Health and Nutrition Examination 
Survey I.72  Values under the 25th percentile was seen as indicative of low protein reserves. 
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2.3.7 Abdominal ultra-sonography 
Abdominal ultrasound was done at the Department of Radiology at Tygerberg Hospital.  The 
ultrasound was classified as normal if no enlarged lymph-nodes were found in the abdomen.  
Children were classified with abdominal lymph-node involvement if enlarged lymph-nodes were 
found in the abdomen, liver, spleen and pericardium. 
 
2.3.8 Dietary intake 
The medical officer working on the larger BMS study of which this study formed a part, obtained 
the informed consent and conducted the initial interview.  The researcher therefore often did not 
have direct contact with the parent or guardian and could not conduct the 24-hour recall or food 
frequency questionnaire (FFQ) at the time of enrolment.  The data from the subjects with whom 
an interview was conducted by the researcher is included in the results section.  The mean 
intake from the FFQ and 24-hour recall was compared with the analysis of the BHCD menu.  
Theoretically the children would show catch-up growth if the hospital diet provide more nutrients 
than the regular intake as determined by the FFQ and 24-hour recall. 
 
2.3.8.1 24-hour recall 
An open-ended questionnaire based on the 24-hour recall questionnaire developed for the 
National Food Consumption Survey73 was used to obtain dietary intake during a 24-hour period.  
The researcher asked the parent or guardian to recall all foods, beverages and snacks 
consumed by the child during a typical 24-hour period.  Detailed descriptions of all food and 
beverages were recorded including portion sizes and the cooking method.  Commonly eaten 
portion sizes in gram or ml units were included in the questionnaire.  The portion sizes were 
estimated by using standard household utensils as well as food models from the Department of 
Human Nutrition of the University of Stellenbosch.74,75.  The questionnaire was not validated 
before commencement of the study.  Data obtained was recorded on the 24-hour recall sheet 
(Appendix 2). 
 
2.3.8.2 Food frequency questionnaire 
A quantitative food frequency questionnaire (Appendix 3), based on the FFQ used in for the 
National Food Consumption Survey73 was used to assess food frequency over the preceding 
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year or the preceding six months in babies younger than one year, prior to admission to hospital.  
The parent or guardian was asked to recall how often food groups are consumed and the portion 
size of foods from the different food groups.  The portion sizes were estimated using standard 
household utensils and selected food models.74,75,76  The questionnaire was not validated prior to 
the commencement of this study.  The researcher recorded the type and estimated quantity of 
food consumed by the child. 
 
2.3.9 Collection of blood specimens 
Blood specimens from each child were draw within one week of enrolment in the study and 
again four months after the start of TB treatment.  The children were nil per mouth from 
midnight.  A local anaesthetic jelly was applied before an indwelling catheter was inserted and 
blood drawn by the medical officer and assisted by the nursing sister on the study. 
 
2.3.9.1 Pharmacokinetic study 
RMP plasma concentrations were measured within a week of enrollment in the study and again 
four months after the start of TB treatment.  The study‟s registered nurse administered the 
medication.  Blood specimens were taken at intervals of 45 minutes, 90 minutes, 3, 4 and 6 
hours after the dosing by the medical officer (MO).  The blood specimens was immediately 
placed on ice and centrifuged within 30 minutes.  A plasma sample of 1ml was stored in poly-
propolene tubes at -80˚C and protected from light until analysed.  The specimens were analysed 
for RMP by high pressure liquid chromatography with ultraviolet detection, measuring to 0.3 
µg.ml-1 of RMP, at the Department of Pharmacology at the University of Cape Town. 
 
2.3.9.2 Biochemical analysis 
The African Micronutrient Research Group laboratory of the Department of Human Nutrition at 
the University of Stellenbosch did the following analyses: 
Vitamin A – Vitamin A was determined quantitatively by High Performance Liquid 
Chromatography.  The coefficient of variation for standards used for the normal value was 
3.7%.77 
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Vitamin C – Total ascorbic acid was determined spectrophotometrically by measuring the orange 
colour in a coupling with 2 – 4 – dinitrophenylhydrazine.  The coefficient of variation for 
standards used for the normal value was 7.8%.78 
 
Vitamin E – Vitamin E was determined quantitatively by High Performance Liquid 
Chromatography.  The coefficient of variation for standards used for the normal value was 
9.8%.79 
 
Pyridoxine – Vit. B6 was determined enzymatically (Tyrozine decarboxylase) and measured by 
radioactive Tyrosine (C14).  The coefficient of variation for standards used for the normal value 
was 6.5%.80 
 
PathCare Laboratories (Cape Town, South Africa) analysed the: 
Magnesium – The Roche Hitachi 917 was used to determine magnesium by the Xylidyl-Blue 
reaction.81  The coefficient of variation for standards used for the normal value was 2.3%. 
 
Iron – Serum iron was determined by colorimetric assay.82  The coefficient of variation for 
standards used for the normal value was 6.7%. 
 
Haemoglobin – Flow-through technology or light scatter was used to determine haemoglobin 
with the Bayer Advia 120.81  The coefficient of variation for standards used for the normal value 
was 2.3%. 
 
Ferritin – Ferritin was determined by an antigen/antibody complex and turbidimetric 
measurement.81  The coefficient of variation for standards used for the normal value was 5.0%. 
 
Iron-binding capacity – IBC was calculated from serum iron and transferrin.83  No coefficient of 
variation, as it is a calculated value. 
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AST – International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) method 
without pyridoxal phosphate.84  The coefficient of variation for standards used for the normal 
value was 5.7%. 
 
GGT – L-y-Glutamyl Transferase (5-amino-2-nitrobenzoate) SZASZ.85  The coefficient of 
variation for standards used for the normal value was 7.0%. 
 
ALT – IFCC method without pyridoxal phosphate.86  The coefficient of variation for standards 
used for the normal value was 6.7%. 
 
2.3.10 Assessment of HIV and immunological status 
The HIV-status of some of the children was done before admission to BHCD.  Counseling of the 
parents or legal guardians preceded HIV-testing and written informed consent was obtained.  
The counseling was done by the social worker of BHCD (in English or Xhosa) and the Medical 
Officer involved in the study (in Afrikaans or English). 
 
If a child was tested HIV positive before enrolment in the study the information was obtained 
from the referring hospital‟s file and therefore we do not know what method was used to 
determine HIV-status.  HIV status determined after enrolment in the study was done by enzyme-
linked immunosorbent assay (ELIZA) by Pathcare (Cape Town, South Africa).  HIV testing was 
done using the Abbott Axsym instrument, coefficient of variation is not applicable as only a 
positive or negative result is obtained. 
 
The CD4 lymphocyte count was done by flow-cytometry and had a coefficient of variation of 
25%.  Immunological status was categorised by age as no evidence of suppression, moderate 
suppression or severe suppression.87,88 
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Table 2.1: Immunologic categories for HIV-infected children based on age-specific CD4 T-
lymphocyte count 
Immunologic catagory Cells/µl 
<12 months 1-5 years 6-12 years 
No evidence of 
suppression 
≥1 500 ≥1 000 ≥500 
Evidence of moderate 
suppression 
750 – 1 499 500 - 999 200 - 499 
Severe suppression <750 <500 <200 
From: MMWR Vol. 46/ No. RR 1287 
 
2.4 Data Analysis 
Patient information was entered continuously during the course of the study by the researcher 
anonymously onto coded case report forms and computerized for analysis.  Bio-equivalence, the 
occurrence of toxicity, nutritional and disease status and the outcome of disease management 
was compared between the two study groups (HIV-infected and HIV-non-infected).  Data was 
recorded in an Excel spreadsheet and analyzed with STATISTICA version 8.0.  Basic statistics 
like means, medians, quartiles and standard deviations was used to describe continuous and 
ordinal variables and frequency tables for nominal variables. 
 
All bio-equivalence data points was analysed using paired t-test in the case of a normal 
distribution or Wilcoxon Sign Rank test in data not normally distributed.  The bio-equivalence 
parameters were also subjected to Hauschler's analysis of the 95% confidence interval.  When 
nominal variables were compared to other nominal variables appropriate chi-square tests was 
used.  All statistical analyses were done with a significance level of 5%. 
 
2.4.1 Analysis of anthropologic measurements 
Information from the National Centre for Health Statistics (NCHS) was used to generate Z-
scores and to determine the nutritional status of the children.  Malnutrition was defined as 
stunting, wasting or underweight as defined by the NCHS classifications recommended by the 
WHO66,68.  Height for age (H/A), weight for age (W/A) and height for weight (W/H) indicators 
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were expressed as z-scores or standard deviations (SD) below the median NCHS/WHO 
international reference standard. 
 
Children were classified as severely malnourished if the z-scores were more than 3 standard 
deviations (SD) below the median NHCS/WHO international reference standard.  Z-scores 
between -2.0 and -2.99 SD below the median NHCS/CDC/WHO international reference standard 
were classified as moderately malnourished 
 
Stunting (H/A ≤-2SD) was used to indicate an overall slowing of skeletal growth that occured 
over a long period of time.  Wasting (W/H ≤-2SD) was used to signify a loss in tissue and fat 
mass that occurred over a shorter period of time.  Underweight (W/A≤-2 SD) was used as an 
indicator of poor weight gain within a particular age group. 
 
Skinfold thickness measurements were used to determine body composition and to evaluate 
changes in the distribution of fat in the disease groups.  The assumption is made that triceps 
skinfold (TSF) and subscapular skinfold (SSF) measures energy reserves stored as fat and arm 
muscle area (AMA) reflect reserves stored as muscle protein.  Values were compared to 
percentiles from the United States Health and Nutrition Examination Survey I.72  Values under 
the 25th percentile were seen as indicative of low protein or fat reserves.89 
 
2.4.2 Dietary analysis 
Once the researcher had ensured that all data were collected and questionnaires completed 
fully, data recorded on the FFQ and 24-hour recall questionnaire was entered into the computer 
using Foodfinder III software, designed by MRC.  The data entered was crosschecked to ensure 
correct entry coding and correct quantities. 
 
All dietary data was quantified using the South African RNID food composition tables.  Energy 
was compared with the Recommended Dietary Allowance (RDA) values, the standard approach 
used at the time for the purpose.  The dietary data are expressed as recommended daily intake 
per age group.  Nutrient intake was compared using the RDA reference where a cut-off point of 
67% of the recommended intake was used to describe inadequacy of nutrient intake.94 
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2.4.3 Anti-tuberculosis drugs 
Published reference ranges for RMP have suggested that 2 hour concentrations of <8µg/ml 
should be regarded as low and <4µg/ml as very low.90  As all the children‟s values was low, it 
was decided to classify low RMP values as <4µg/ml.  INH levels of <3.0µg/ml at 2 hours was 
classified as low.90 
 
2.5 Ethics Considerations 
The Committee for Human Research of the University of Stellenbosch approved the study 
(2003/054/N). 
 
2.5.1 Informed consent 
The parents or legal guardians gave written informed consent for the children‟s participation in 
the study and for HIV testing if the child‟s HIV status was not known.  A child was excluded from 
the study if written informed consent to participate was refused or could not be obtained.  The 
consent forms were translated into Afrikaans and Xhosa for non-English speaking participants.  
Written informed consent were obtained after the information sheet had been explained in 
English or Afrikaans by the Medical Officer involved in the study.  For Xhosa speaking parents or 
legal guardians who did not understand English or Afrikaans, the Xhosa informed consent form 
and information sheet were explained by a Xhosa-speaking nursing sister (Appendix 1). 
 
2.5.2 Patient confidentiality 
Patient confidentiality was protected by anonymous coding of specimens.  Demographic and 
clinical data was stored in the researchers‟ office at BHCD making use of anonymous coding.  
The data was only accessible by the researchers. 
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CHAPTER 3:  RESULTS 
  31 
3.1 Sample Characteristics 
Sixty children, 26 HIV-infected and 34 HIV-uninfected were enrolled in the study.  Four children 
(all HIV-infected) were transferred back to referring hospitals shortly after enrolment due to 
complications that could not be handled at BHCD and three children were discharged from 
hospital after completion of the first pharmacokinetic study.  As a result these seven children 
were excluded from the study and their data not included in the analysis.  Results from 
anthropometric data for the remaining 19 HIV-infected and 34 HIV-uninfected children were 
included in the final analysis.  Liver enzyme analyses were not done for 2 children at enrolment 
and 3 at 4 months, while vitamin status was not determined for 1 child at enrolment and 2 at 4 
months and they were therefore not included in the analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Characteristics of sample 
 
420 Paediatric patients was admitted to BHCD and screened during the study period
68 Patients met the inclusion criteria
Consent was obtained from 60 patients
• 26 HIV infected
• 34 HIV uninfected
8 Patients was excluded:
• 1 refused consent
• 7 patients did not have a parent or legal
guardian to give consent
Of 60 patients enrolled, 7 HIV infected dropped out as follows:
• 3 was discharged from hospital after enrolment 
• Blood could not be obtained from 1 patient
• 3 patients was transferred to referring hospitals with complications
Final analysis was done for:
• 19 HIV infected
• 34 HIV uninfected 
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3.2 Demographic, Diagnostic and Clinical Features 
Demographic, diagnostic and clinical features of the children studied are summarized in Table 
3.1.  Of the 53 children studied, 29 were male and 24 were female.  HIV positive children 
comprised 35.8%, whereas 64.2% were HIV negative.  The ages of the children studied ranged 
from 5 months to 12 years, with more than 50% under 4 years of age.  The age distribution 
indicates that the largest number (26.4%) of children were in the 48-72 month category, followed 
by those between 24-48 months of age (24.5%).  The period between the start of treatment and 
enrolment in the study did not differ between the HIV positive and HIV negative children and was 
34.2 days and 38.0 days respectively. 
 
Overall a culture of M tuberculosis was obtained from 28 (53.8%) children and in a further 3 HIV-
uninfected children with negative cultures, acid fast bacilli (AFB) were seen on microscopy of 
gastric aspirates.  Household TB contact was high (69.8%) and did not differ significantly 
between the HIV-infected and HIV-uninfected children (p=0.82).  Pulmonary TB was more 
common in the HIV-infected children (94.7%) compared to 79.4% of HIV-uninfected children but 
the difference was not significant (p=0.72), but tuberculous meningitis was more frequent in the 
HIV-uninfected children than HIV-infected children, with 55.8% and 36.8% respectively, but this 
difference was also not significant (p=0.16).  Culture and microscopy were not carried out on 3 
HIV-uninfected children.  Mantoux test was not read in one HIV-uninfected child and, as 
expected, only a minority (22%) of HIV-infected children had a positive Mantoux test. 
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Table 3.1: Demographic, diagnostic and clinical features of children with and without HIV-
infection 
 HIV positive 
with TB N=19 
(%) 
HIV negative 
with TB N=34 
(%) 
Total N 
(%) 
P-
value 
Gender Male 11 (37.9) 18 (62.1) 29 (54.7)  
 Female 8 (33.3) 16 (66.6) 24 (45.3)  
Total 19 (35.8) 34 (64.2) 53  
Age (in months) 6-<12 2 4 6 (11.3)  
 12-<24 3 7 10 (18.9)  
 24-<48 6 7 13 (24.5)  
 48-<72 7 7 14 (26.4)  
 ≥72 2 8 10 (18.9)  
Days from start of treatment to 
enrolment in study 
34.2 38.0  0.49 
Culture of M tuberculosis or 
AFB seen on microscopy 
10 (41.6) 
24 done 
18 (64.2) 
28 done 
28 (53.8) 0.16 
Household TBcontact 14 (73.6) 23 (67.6) 37 (69.8) 0.82 
Clinical features Intra-
thoracic TB 
18 (94.7) 27 (79.4) 45 (84.9) 0.72 
 Tuberculous 
meningitis 
7 (36.8) 19 (55.8) 26 (49.1) 0.16 
Mantoux test ≥15mm 2 (10.5) 30 (88.2) 32 (60.3) <0.001 
 10-14mm 2 (10.5) - 2 (3.7)  
 5-9mm - - -  
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Section A:  Baseline 
3.3 Baseline Features (Table 3.2) 
3.3.1 Immunological status 
The mean CD4 count of the 19 HIV-infected children at enrolment was 515.7µl-1.  According to 
the age-specific T-lymphocyte counts of the children, the largest proportion was classified as 
severely compromised immunity (47.4%), followed by 31.6% moderately compromised immunity 
and 21.0% had no immuno-suppression.  (Appendix 4) 
 
3.3.2 Anthropometry 
MUAC was low in 20.8% of HIV-infected patients and 23.5% of HIV-uninfected patients, and the 
difference was not significant (p=0.410).  There was no significant difference in stunting or 
wasting between HIV-infected and HIV-uninfected children, but underweight for age was 
significantly more common (p=0.003) amongst the HIV-infected children (31.5%) than amongst 
the HIV-uninfected children (2.9%). between and.  (Figure 3.2) 
 
The difference in low (under the 25th percentile) AMA between HIV-infected (84.2%) and HIV-
uninfected (79.4%) children was not significant with a p-value of 0.665.  TSF was low in 63.1% 
of HIV-infected patients and 41.2% HIV-uninfected patients (p=0.123 not significant).  A 
significant difference (p=0.039) in the frequency of low SSF was seen between HIV-infected 
(26.3%) and HIV-uninfected (5.8%) children.  Muscle mass, as measured by AMA was therefore 
more depleted in both groups than fat mass at enrolment. 
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Figure 3.2 Effect of HIV-status on underweight (W/A) 
 
3.3.3 Ultrasound 
Abdominal nodes were indicating abdominal TB involvement were visualized on ultrasound in 
36.8% of HIV-infected children with 26.4% of HIV-uninfected children (p= 0.43354).  A total of 
30.2% had abdominal involvement at enrolment.  All of the HIV-uninfected children had one area 
of abdominal involvement, while 57% of HIV-infected children had two or three areas of 
involvement, including the liver, spleen and kidneys.  (Table 3.2) 
 
Abnormal abdominal ultrasound showing abdominal lymph-node enlargement was compared to 
nutritional status.  Nutritional status, as determined by weight for height (p=0.41), weight for age 
(p=0.1099) and height for age (p=0.2271), was not significantly affected by abdominal lymph-
node involvement. 
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3.3.4 Liver enzymes 
AST was elevated in 29.4% of children studied.  There was a marked, but insignificant 
(p=0.0541) difference between the raised level of AST in HIV-infected (47.1%) and HIV-
uninfected (20.5%) children. Despite the increased values on enrolment only two HIV-infected 
and two HIV-uninfected children had ALT values increased >X3 normal. Similarly AST values 
>X3 normal were found in only one HIV-infected child and two HIV-uninfected children. HIV 
infection had no effect on the raised levels of ALT (11.7%) and GGT (35.2%) of the children.  
(Table 3.2) 
 
3.3.5 Biochemical values 
More than 30% of the children had sub-optimal vitamin A, pyridoxine and haematocrit levels.  
Magnesium, iron and haemoglobin levels were sub-optimal in over 50% of the children studied.  
It is notable that no children in either group had lower than normal zinc levels at enrolment and 
that selenium, vitamin C and vitamin E values were normal except for a small minority of 
children. (Table 3.2) 
 
A marked, but not significant, difference was seen in pyridoxine (p=0.0738), IBC (p=0.1426) and 
Hb (p=0.5148) levels between HIV-infected and HIV-uninfected children.  A larger number of 
HIV-infected than HIV-uninfected children had sub-optimal levels of pyridoxine, IBC and Hb.  
Low ferritin levels (p=0.0208) were significantly more prevalent in the HIV-uninfected children, at 
30.3%, compared to 5.2% HIV-infected children.  Low Hct levels were significantly more 
prevalent (p=0.00001) in HIV-infected (78.9%) children compared to HIV-uninfected (14.7%) 
children at enrolment. (Table 3.2) 
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Table 3.2: Anthropometric, ultrasound and biochemical characteristics of children at 
baseline 
 HIV positive 
with TB N (%) 
HIV negative 
with TB N (%) 
Total N (%) P-value 
CD4 count (mean) 515.7 µl-1    
Anthropometry MUAC 
(≤13.5cm) 
5 (20.8) 8 (23.5) 13 (24.5) 0.410 
 Stunted 6 (31.5) 5 (14.7) 11 (20.7) 0.449 
 Wasted 1 (5.2) 0 1 (1.8) 0.766 
 Underweight 6 (31.5) 1 (2.9) 7 (13.2) 0.003 
 AMA <25th 
percentile 
16/19 (84.2) 27/34 (79.4) 43/53 (81.1) 0.6651 
 TSF <25th 
percentile 
12/19 (63.1) 14/34 (41.2) 26/53 (49.1) 0.1231 
 SSF <25th 
percentile 
5/19 (26.3) 2/34 (5.8) 7/53 (13.2) 0.0390 
Abdominal nodes visualized on 
ultrasound 
7 (36.8) 9 (26.4) 16 (30.2) 0.4335 
Liver enzymes 
(elevated) 
AST 8/17 (47.1) 7/34 (20.5) 15 (29.4) 0.0541 
ALT 2/17 (11.7) 4/34 (11.7) 6 (11.7) 0.8274 
GGT 6/17 (35.2) 12/34 (35.2) 18 (35.2) 0.3826 
Biochemical 
(sub-optimal 
levels) 
Vitamin A 7/19 (36.8) 10/33 (30.3) 17 (32.6) 0.0590 
Vitamin C 0/19 (0) 1/34 (2.9) 1 (1.8) 0.2520 
Vitamin E 2/19 (10.5) 4/33 (12.1) 6 (11.5) 0.6022 
Pyridoxine 10/19 (52.6) 6/34 (17.6) 16 (30.1) 0.0738 
Selenium 0/19 (0) 2/30 (6.6) 2 (4.08) 0.4125 
Magnesium 13/16 (81.2) 26/33 (78.7) 39 (79.5) 0.8402 
Zinc 0/19 (0) 0/33 (0) 0 0.4738 
Fe 11/19 (57.9) 22/33 (64.7) 33 0.6602 
IBC 4/16 (25) 2/33 (6.1) 6 (12.2) 0.1426 
Hct 15/19 (78.9) 5/34 (14.7) 20 (37.7) 0.00001 
Ferritin 1/19 (5.2) 10/33 (30.3) 11 (21.1) 0.0208 
Hb 16/19 (84.2) 18/34 (52.9) 34 (64.1) 0.5148 
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3.3.6 Dietary intake 
The researcher often did not have direct contact with the parent or guardian of a child as the 
enrolment and initial interview was done by the Medical Officer of the larger study in which this 
study was nested.  The 24-hour recall and food frequency questionnaire (FFQ) at the time of 
enrolment was therfore not done for all children.  Diet histories, including a food frequency 
questionnaire and 24-hour recall could only be obtained from 15 children, 9 HIV-uninfected and 
6 HIV-infected.  The data from these questionnaires was compared (Table 3.3) to the average 
daily intake from the 3 week cycle menu of BHCD at the time of the study. 
 
Intake of less than 67% of the recommended dietary allowance (RDA) was defined as low.  The 
BHCD diet contributed more than 67% of macro- and micronutrients, i.e the minimum, in all 
cases, but only met 100% of RDA for protein, magnesium, vitamin A and vitamin C. 
 
From the FFQ the children‟s usual dietary intake of zinc and vitamin E was low.  The FFQ 
indicated 100% of the RDA for protein was met by 80% of children and 86.67% reported 100% 
RDA intake of magnesium.  The 24-hour recall showed similar results, 86.67% met 100% RDA 
for protein and 80% met 100% RDA for magnesium.  The 24-hour recall showed that less than 
60% of respondents consumed 100%of RDA for energy, iron, zinc, selenium, pyridoxine and 
vitamins A,C and E.  According to the 24-hour recall all of the selected nutrients listed in Table 
3.3 were ingested in amounts higher than 67% of the RDA.  The amount of protein reported was 
especially high at 255.1% and 317.1% of the RDA from the FFQ and 24-hour recall, 
respectively. 
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Table 3.3 Comparison of mean dietary intake derived from Food frequency 
questionnaire, 24-hour recall and BHCD diet, expressed as percentage of age-specific 
RDA at baseline 
Nutrient Food frequency questionnaire 24-hour recall BHCD 
Mean 
(SD) 
Median 100% 
RDA 
met, 
N=15 (%) 
Mean 
(SD) 
Median 100% 
RDA, 
met, 
N=15 (%) 
Energy 86.1  
(103.5) 
57.0 4  
(26.67) 
103.7  
(100.5) 
70.7 2  
(13.33) 
68.3 
Protein 255.1  
(427.9) 
129.2 12  
(80.00) 
317.1  
(382.1) 
201.7 13  
(86.67) 
212.9 
Iron 92.3  
(160.0) 
41.0 4  
(26.67) 
152.9  
(240.6) 
60.0 2  
(13.33) 
71.0 
Magnesium 215.0  
(301.5) 
127.5 13  
(86.67) 
247.9  
(270.1) 
160.0 12 
(80.00) 
157.5 
Zinc 62.9  
(87.1) 
39.5 2  
(13.33) 
92.7  
(97.6) 
64.5 1  
(6.67) 
96.7 
Selenium 132.7  
(212.8) 
59.5 5  
(33.33) 
96.1  
(97.8) 
60.3 5  
(33.33) 
82.0 
Vitamin A 186.1  
(277.0) 
103.8 9  
(60.00) 
253.2  
(291.9) 
152.1 8  
(53.33) 
120.6 
Vitamin C 108.8  
(117.0) 
77.5 6  
(40.00) 
194.1  
(296.6) 
73.3 5  
(33.33) 
106.6 
Vitamin E 54.0  
(48.4) 
39.7 3  
(20.00) 
116.0  
(164.8) 
66.0 2  
(13.33) 
85.3 
Pyridoxine 71.6  
(88.7) 
47.5 3  
(20.00) 
87.7  
(90.8) 
54.6 1  
(6.67) 
94.9 
 
3.3.6.1 Diet history  
The nutritional status of the children from whom a diet history could be obtained, as classified by 
anthropometric z-scores, was not consistent with the nutritional status of the study sample. 
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(Table 3.4)  The information obtained from the diet history can therefore not be extrapolated to 
the whole sample studied. 
 
Table 3.4 Comparison of nutritional status in diet history sample to total study 
sample 
Classification Enrolment 
Diet history obtained, N=15 
(%) 
Children studied, N=53 (%) 
Normal 13 (86.6) 35 (66.0) 
Stunted 1 (6.6) 11 (20.7) 
Underweight 1 (6.6) 7 (13.2) 
Wasted 0 (0.0) 0 (0.0) 
 
Two children from which a diet history was obtained was classified as malnourished.  Energy 
intake from the FFQ was low (57.0% of RDA) in the underweight child, while protein intake was 
normal (106.2% of RDA).  The stunted child had a energy intake of 72.1% of RDA and protein 
intake of 151.3% of RDA. 
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Section B: Follow up 
3.4 HIV Status of Children 
The immunological status of HIV-infected children was tested at enrolment and after four months 
of treatment.  The CD4 counts of HIV-negative children were not determined.  The clinical 
presentations of the HIV-infected children varied during the period of hospitalization.  The mean 
CD4 count of the 19 HIV positive children was 515.7µl-1 at enrolment and the mean of the 18 at 
month 4, 589.5µl-1. 
 
Table 3.5 indicates that 31.6% of HIV-positive children were classified as moderately immuno-
compromised at enrolment, compared to 55.5% at 4 months of treatment.  At enrolment the 
immunity of 47.4% was severely compromised, which decreased to 27.8% at month 4.  The CD4 
count of 1 child was unknown at 4 months follow-up.  Age-specific immunologic categories are 
given in Appendix 4. 
 
HAART was commenced within the first 4 months of evaluation in 7 HIV-infected children, while 
2 had been on treatment for at least two years before admission.  A further 6 children 
commenced on HAART after the 4 months evaluation and 4 children were not placed on 
HAART.  The mean CD4 count of the children started on HAART increased from 538.9µl-1 to 
675.1µl-1, which was not significant.  One child‟s CD4 count decreased.  Of these 7 children, 
57.1% were severely immunocompromised and 28.6% were moderately immunocompromised 
at enrolment compared to 28.6% and 42.9%, repectively, at month 4. 
 
Table 3.5: The age-specific immunological status of HIV-positive children studied 
Immunologic category Enrolment, N (%) Month 4, N (%) 
No immuno-suppression 4  (21.0) 3  (16.7) 
Moderately compromised immunity  6  (31.6) 10  (55.5) 
Severely compromised immunity 9  (47.4) 5  (27.8) 
Total 19 18 
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3.5 Nutritional Status 
3.5.1 Anthropometry 
Anthropometric measurements were taken at enrolment and once a month thereafter.  Only 
results at enrolment and 4 months after the start of TB treatment are included, as it is compared 
with data of the pharmacokinetic study which was only taken at these intervals. 
 
3.5.1.1 Weight, height and MUAC 
According to, HIV-status did not have a significant effect on the mean mid-upper arm 
circumference measurements at enrolment (P=0.41) or month 4 (P= 0.76).  (Table 3.6) 
 
Z-scores were used to classify malnutrition in this study.  Stunting (46.27%) and underweight 
(34.51%) were identified as the most common types of malnutrition in both HIV-positive and HIV-
negative children studied (Table 3.7).  Severe malnutrition, classified as z-score <-3 SD below 
the mean NHCS/CDC/WHO International reference standard, was uncommon.  None of the 
children were severely wasted or severely underweight.  Severe stunting did occur in 1 (5.2%) 
HIV-positive child and 2 (5.8%) HIV-negative children, improving at month 4 when no HIV-
positive children were severely stunted and only 1 (2.9%) HIV-negative child. 
 
The effect of HIV-infection on malnutrition was not significant, except for underweight for age at 
enrolment with a p-value of 0.00354.  At month 4 the effect of HIV-infection on underweight was 
not significant (p=0.5474). 
 
There was no change in the number of stunted, wasted or underweight children from enrolment 
to month 4, indicating that there was very little or no catch-up growth on treatment in HIV-
positive or HIV-negative children (Figures 3.3-3.5). 
 
The mean weight of HIV-infected children at enrolment was 12.6kg, which increased to 13.1kg at 
month 4.  HIV-uninfected children showed a significant increase from 13.9kg at enrolment to 
15.0kg at month 4 (p=0.0013). 
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Table 3.6: The mean mid upper arm circumference at enrolment and at month 4 of 
study 
 Enrolment Month 4 
HIV-
positive 
HIV-
negative 
P-value HIV-
Positive 
HIV-
negative 
P-value 
N 19 34  19 34  
MUAC in 
cm (SD) 
11.67 
(1.72) 
12.10 
(1.96) 
0.41 12.57 
(2.17) 
12.77 
(2.58) 
0.76 
 
Table 3.7: Percentage of children malnourished using z-scores, at enrolment and at 
month 4 
Classifi-
cation 
Enrolment N (%) Month 4 (%) 
HIV-pos, 
N=19 
HIV-
neg, 
N=34 
Total,N=
53 
P-
value 
HIV-pos, 
N=19 
HIV-
neg, 
N=34 
Total,N=
53 
P-
value 
Stunted 
(H/A) 
6 
(31.57) 
5 
(14.70) 
11 
(20.75) 
0.4496 6 
(31.57) 
5 
(14.70) 
11 
(20.75) 
0.4189 
Wasted 
(W/H) 
1 
(5.26) 
0 
(0.0) 
1 
(1.88) 
0.7666 1 
(5.26) 
0 
(0.0) 
1 
(1.88) 
0.1973 
Under-
weight 
(W/A) 
6 
(31.57) 
1 
(2.94) 
7 
(13.2) 
0.0035 4 
(21.05) 
3 
(8.82) 
7 
(13.2) 
0.5474 
Stunted 
and 
wasted 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
 0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
 
Malnutrition classified as z-scores <-2 SD below the mean NHCS/CDC/WHO International 
reference standard. 
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Figure 3.3 Relationship between wasting at enrolment and month 4 
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Figure 3.4 Relationship between underweight at enrolment and month 4 
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Figure 3.5 Relationship between stunting at enrolment and month 4 
 
3.5.1.2 Body composition 
At enrolment muscle mass, as measured by AMA, was more depleted in both groups than fat 
mass (Table 3.8).  AMA increased in both groups after 4 months, but more so in the HIV-
uninfected group.  By 4 months the TSF decreased in the HIV-infected group, showing a 
decrease in fat stores, but this measurement increased in the HIV-uninfected group, showing an 
increase in fat stores, although not significantly (Table 3.8).  Low values are classified as below 
the 25th percentile. 
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Table 3.8: Skinfold measurements and AMA 
Measurement Enrolment Month 4 
HIV-
positive N 
(%) 
HIV-
negative 
N (%) 
P-value HIV-
positive N 
(%) 
HIV-
negative 
N (%) 
P-value 
AMA  
(<25th percentile) 
17/19 
(89.4) 
27/34 
(79.4) 
0.6651 15/20 
(75.0) 
22/34 
(64.7) 
0.4982 
TSF 
(<25th percentile) 
12/21 
(57.1) 
14/34 
(41.2) 
0.1231 12/20 
(60.0) 
13/34 
(38.2) 
0.5184 
SSF  
(<25th percentile) 
8/20 
(40.0) 
4/34 
(11.7) 
0.0390 7/20 
(35.0) 
5/34 
(14.7) 
0.0951 
 
3.6 Liver functions 
The anthropometric status of the children was compared to the liver enzymes at enrolment and 4 
months (Table 3.9) of treatment.  Weight for age had a significant negative effect on AST and 
ALT at enrolment with p-values of 0.02166 and 0.02765 respectively.  Wasting had a significant 
negative effect on GGT at enrolment (p=0.03014).  Stunting did not have a significant effect on 
liver enzymes.  Anthopometric status did not have a significant effect on liver enzymes at month 
4.  (Table 3.9)  
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Table 3.9: Elevated liver enzymes compared with nutritional status at enrolment and 
month 4 
Liver 
enzyme 
(normal 
values) 
Enrolment Month 4 
Stunted 
N (%) 
Wasted 
N (%) 
Under-
weight 
N (%) 
Normal 
N (%) 
Stunted 
N (%) 
Wasted 
N (%) 
Under-
weight 
N (%) 
Normal 
N (%) 
AST  
(16-46 µl-1) 
p-value 
5 (45.5) 
0.5906 
1  
(100.0) 
0.1858 
5 (71.4) 
 
0.0216 
5  2 (22.2) 
 
0.8188 
0 (0.0) 
 
1.0000 
1 (14.3) 
 
0.2498 
6  
ALT  
(3-37 µl-1) 
p-value 
3 (27.3) 
 
0.0714 
0 (0.0) 
 
0.9417 
2 (28.6) 
 
0.0276 
1 3 (33.3) 
 
0.6210 
0 (0.0) 
 
0.5114 
2 (28.6) 
 
0.0722 
4 
GGT  
(1-32 µl-1) 
p-value 
5 (45.5) 
 
0.5664 
1 
(100.0) 
0.0301 
5 (71.4) 
 
0.1044 
4 4 (44.4) 
 
0.4587 
1  
(100.0) 
0.1172 
4 (57.1) 
 
0.1554 
6 
Total 13 2 12 10 9 1 7 16 
 
HIV-infection had a significant effect on AST at month 4 (Figure 3.6), with 41% of HIV-infected 
children having elevated AST-levels (p-value 0.02477). 
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Figure 3.6 Effect of HIV-infection on AST at month 4.  0 indicates normal values (16-46 
µl-1) and 1 are elevated values. 
 
3.7 INH-levels 
INH-levels at enrolment and after 4 months (Table 3.10) of treatment were compared to 
nutritional status to determine whether nutritional status had an effect on the bio-availability of 
anti-tuberculosis agents.  Values of <3.0µg/ml at 2 hours after ingestion was considered low. 
 
None of the parameters used to determine nutritional status had a statistically significant effect 
on INH-levels.  In stunting, wasting and underweight INH-levels were normal in more than 50% 
of children.  At 4 months none of the malnourished children had low INH levels. 
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Table 3.10: INH levels compared to nutritional status (%) 
INH-level Enrolment Month 4 
Wasted 
N (%) 
Stunted 
N (%) 
Under-
weight N 
(%) 
Wasted 
N (%) 
Stunted 
N (%) 
Under-
weight N 
(%) 
INH low 0 (0) 2 (18.18) 1 (14.28) 0 (0) 0 (0) 0 (0) 
INH normal 1 (100) 6 (54.54) 4 (57.14) 1 (100) 9 (81.81) 5 (71.42) 
INH high 0 (0) 3 (27.27) 2 (28.57) 0 (0) 2 (18.18) 2 (28.57) 
Total 1 11 7 1 11 7 
*Kruskal-Wallis test, p> 0.05 
 
3.8 Rifampicin (RMP) levels 
RMP levels and abnormal nutritional status parameters were compared to determine a possible 
link between malnutrition and low blood levels of RMP.  RMP concentrations of <4µg/ml was 
regarded as low.  A statistically significant effect of malnutrition on RMP-levels could not be 
determined. (Table 3.11) 
 
Table 3.11: RMP levels compared to nutritional status (%) 
RMP-level Enrolment Month 4 
Wasted 
N (%) 
Stunted 
N (%) 
Under-
weight N 
(%) 
Wasted 
N (%) 
Stunted 
N (%) 
Under-
weight N 
(%) 
RMP low 
(<4µg/ml) 
1 (100) 3 (42.85) 1 (50) 1 (100) 4 (57.14) 1 (50) 
RMP 
(≥4µg/ml)  
0 (0) 4 (57.14) 1 (50) 0 (0) 3 (42.85) 1 (50) 
Total 1 7 2 1 7 2 
* Kruskal-Wallis test, p> 0.05 
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3.9 Biochemical 
Biochemical values of the children were compared between HIV-infection groups at enrolment 
and at 4 months after hospitalization.  The mean values of selected biochemical analyses are 
indicated in Table 3.12.  HIV-infection had a marginally significant effect on selenium, IBC and 
ferritin means at enrolment, with p-values of 0.030, 0.025 and 0.026, respectively.  At the 
assessment 4 months after the start of anti-TB treatment, HIV-infection had a significant effect 
on the mean vitamin C, selenium, pirydoxine and ferritin levels, with p-values of 0.005, 0.012, 
0.001 and 0.002, respectively. 
 
Table 3.12: Mean Biochemical values at Enrolment and Month 4 of observation 
 Enrolment Month 4 
HIV 
positive 
HIV 
negative 
P-value* HIV 
positive 
HIV 
negative 
P-value* 
Vitamin A (>20µg.dl-1) 24.68 26.54 0.5225 22.61 27.02 0.0591 
Vitamin C  
(0.25-1.20mg.dl-1) 
0.89 1.04 0.2520 0.75 1.02 0.0050 
Vitamin E (>6mg.l-1) 9.63 9.23 0.6022 8.20 9.35 0.1252 
Pyridoxine (6-20ng.ml-1) 8.32 11.28 0.1189 6.75 14.76 0.0010 
Selenium (46-143µg.l-1) 69.00 91.9 0.0308 75.11 108.51 0.0126 
Magnesium  
(0.6-1.0mmol.l-1) 
0.92 0.93 0.8100 0.82 3.57 0.3105 
Zinc (7-22µmol.l-1) 18.57 18.03 0.7513 16.15 17.99 0.1354 
Fe (9.5-21.3µmol.l-1) 11.12 8.79 0.2998 12.50 12.01 0.8423 
IBC 49.94 57.17 0.0254 48.98 53.23 0.1207 
Hct (0.33-0.39) 0.31 0.36 0.7525 0.31 0.36 0.7525 
Ferritin (20-300µg.l-1) 72.04 36.54 0.0267 77.95 31.45 0.0028 
* Welch two sample t-test 
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3.10 Diet history  
No follow-up data was collected.  As all the children were hospitalised at BHCD, the hospital diet 
was analysed and used for comparison. 
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CHAPTER 4:  DISCUSSION AND LIMITATIONS 
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This study aimed to assess the nutritional status of children with TB, with and without HIV-
infection, and to determine the effect that poor nutritional status has on absorption of anti-
tuberculosis agents, hepatotoxicity and the effect of abdominal lymph-node involvement on 
nutritional status.  Malnutrition was evident in 24.52% of the children.  HIV-infection had a 
significant negative effect on weight for age, but other anthropometric indicators were not 
affected.  Anthropometric parameters were found not to have an effect on blood levels 
(absorption) of anti-tuberculosis agents.  Elevated liver enzymes indicating hepatotoxicity were 
affected by wasting and underweight, but stunting did not have a significant effect.  Nutritional 
status was not affected by abdominal lymph-node involvement as determined by ultrasound. 
 
The most prevalent forms of malnutrition in this study were stunting and underweight.  No 
change occurred in the amount of stunting and wasting from enrolment to month 4 of the study 
and only a small and insignificant change was found in underweight for age.  HIV-infection did 
not have a significant effect on stunting or wasting, but did significantly affect weight for age at 
enrolment.  Mean weight gain was significant in HIV-uninfected children.  This shows that there 
was no or very little catch-up growth in the HIV-infected group during the time on treatment.  The 
fact that the HIV- infected group showed no catch-up growth highlights the many factors possibly 
contributing to failure to thrive.  One of the contributing factors may be a sub-optimal hospital 
diet and needs to be further investigated. 
 
The assumption was made that triceps skinfold and subscapular skinfold measurements indicate 
energy reserves stored as fat, and arm muscle area reflect muscle protein stores.  Muscle mass 
was more depleted at enrolment than fat mass in HIV-positive and HIV-negative children.  
Muscle mass increased by month 4, but more so in the HIV-negative group, indicating that HIV-
uninfected children had a better response to adequate intake while on TB treatment.  The 
severity of illness determines the metabolic stress in an individual.  This may suggest that HIV-
infected children is prone to more serious TB-infection or that HIV-infection exercises additional 
metabolic stress. 
 
Fat distribution was disproportionate in both HIV-positive and HIV-negative children at 
enrolment, with subscapular skinfold higher in both groups than TSF.  By month 4 the TSF 
decreased in the HIV-positive group, showing a decrease in fat stores, but these measurements 
  55 
increased in the HIV-negative group, showing an increase in fat stores, although not significantly 
so. Preferential fat storage during recovery from catabolic stress has been reported74 and should 
be further investigated in this age group to make a more definite conclusion.  Many patients 
remain underweight after 6 months of TB treatment, even when treatment is successful.74  An 
increase in fat stores would be expected on an adequate diet and treatment and the failure of 
the HIV-positive children to achieve this may be due to altered metabolism as part of the 
inflammatory and immune responses. 
 
In HIV-infected children at enrolment severely compromised immunity was most prevalent, but 
this improved to moderately immuno-compromised being most prevalent at month 4.  Therefore 
despite nutritional status not improving the immune-status of HIV-positive children improved in 
hospital.  This may be due to better nutrition, less infections, adequate TB treatment or a 
combination thereof.  HIV-infection did not have a significant effect on nutritional status in this 
study.  Only a minority of children (31.57%) were placed on HAART towards the end of the 
evaluation and did not have a significant effect on the immunological status of the children. 
 
A significant number of children with primary tuberculosis will also have involvement of the 
abdominal lymph nodes in addition to those in the chest as result of the retrograde spread of 
mycobacteria.87,88  In most cases this does not lead to overt abdominal tuberculosis, but may 
compromise the lymphatic drainage of the gut and so contribute to the development of 
malnutrition or affect the absorption of drugs.  Neither nutritional status nor serum concentrations 
of RMP or INH were significantly affected by abdominal lymph-node involvement determined by 
abdominal ultrasound. 
 
Poor nutritional status is one of the most widely accepted risk factors for anti-tuberculosis 
therapy induced hepatotoxicity.  Underweight for age had a significant effect on AST and ALT 
and wasting had a significant effect on GGT.  After 4 months of treatment malnutrition had no 
effect on liver enzymes.  Stunting, indicative of longstanding undernutrition had no effect on liver 
enzymes.  As malnutrition did not have an effect on hepatotoxicity after 4 months of treatment, 
the initial effect might be due to the TB-infection in combination with malnutrition rather than 
malnutrition alone. 
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Selected vitamins‟ status was analyzed.  There was a significant change in vitamin A and 
vitamin C from enrolment to month 4 of the study.  Vitamin A status improved, but vitamin C 
decreased.  It has been found that there may be a notable decline in vitamin C with stress, 
inflammation or disease.91  Vitamin E and pyridoxine values did not change significantly, even 
though the children received a multivitamin syrup daily.  The mean plasma pyridoxine 
concentration did not differ significantly between HIV-infected and HIV-uninfected children at 
enrolment.  At the second assessment after 4 months treatment the mean pyridoxine 
concentrations differed significantly between HIV-infected and HIV-uninfected children.  Plasma 
pyridoxine concentrations in HIV-infected children did not differ between those children who 
were, and were not, receiving HAART.  The low plasma pyridoxine concentrations found may be 
the result of an ongoing acute phase response and not a vitamin B6 deficiency, but it has been 
found in adult HIV-infected patients that pyridoxine-intakes more than twice the recommended 
daily allowance are associated with improved survival.91  Despite pyridoxine supplementation 
and a diet containing adequate amounts of pyridoxine , sub-optimal concentrations were still 
found after 4 months of treatment in 47% HIV-infected children compared 52% after one month 
of treatment.  Sub-optimal concentrations improved from 18% after 1 month to 6% after 4 
months‟ treatment in HIV-uninfected children.  Additional pyridoxine supplementation of HIV-
infected children receiving INH would be advisable. 
 
In summary the nutritional categorization of children with TB, with or without HIV co-infection, did 
not improve during hospitalization, despite treatment of TB, although mean weight increased, 
significantly so in HIV-uninfected children.  Further study is necessary to determine whether 
nutritional support can be improved to enable the children to have a better disease outcome. 
 
  57 
 
 
 
 
 
 
 
CHAPTER 5:  RECOMMENDATIONS 
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For future study the following should be considered: 
 
 Increased sample size is recommended as more than 25% of HIV-positive subjects 
enrolled were not included in the final analysis. 
 
 Vitamin status should be investigated further to evaluate the supplements given and the 
vitamin content of the hospital diet, focussing particularly on pyridoxine supplementation to 
HIV positive children. 
 
 The nutritional status of all children with TB should be assessed and those with stunting or 
wasting should be referred for nutritional support. 
 
 The diet at BHCD should be evaluated extensively and a dietitian should be involved in 
menu-planning to ensure provision of nutritionally adequate diets. 
 
 BHCD needs a dietitian to detect, monitor and treat malnutrition in this facility and give 
training and support to care-givers when the children are discharged. 
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Appendix 1: Informed consent forms 
 
BMS: Secure the Future 
Paediatric HIV/TB Research Consortium 
University of Cape Town /University of Stellenbosch 
THE PHARMACOKINETICS AND TOXICITY OF ANTITUBERCULOSIS AGENTS AND 
OTHER CO-ADMINISTERED DRUGS IN CHILDREN, WITH AND WITHOUT HIV INFECTION 
AND THEIR RELATIONSHIP TO NUTRITIONAL STATE AND TO THE NAT2 ACETYLATOR 
GENOTYPE AND PHENOTYPE. 
Short title: The pharmacokinetics and toxicity of antituberculosis agents in children, 
with and without HIV infection. 
Informed Consent Documents. 
Introduction 
HIV/AIDS and tuberculosis are major health problems in South Africa.  When they occur 
together they can make one another's outcome worse.  There is uncertainty as to what are the 
best dosages of antituberculosis medicines that should be used in children with tuberculosis, 
both with and without HIV infection.  On the one hand giving too little of the medicine may be 
insufficient to kill all of the tuberculosis germs and so lead to the recurrence of the tuberculosis; 
on the other hand giving too much of a medicine may cause toxic effects.  It is also possible that 
children with HIV infection may be more prone to toxic side effects of the antituberculosis 
medicines.  During this study we will measure the way that children with tuberculosis absorb and 
metabolise antituberculosis medicines and evaluate whether HIV infection and its complications, 
malnutrition or tuberculosis itself have any effect upon the way that children with tuberculosis 
absorb and react to antituberculosis medicines. 
This study is sponsored by Bristol Myers Squibb – Secure the Future Foundation.  
The doctors in charge of this study at this site are: Professor Peter Donald of theDepartment of 
Paediatrics and Child Health of the Faculty of Health Sciences, the University of Stellenbosch 
and Professor Gregory Hussey of the School of Child and Adolescent Health, University of Cape 
Town. 
Before you decide if you want your child to be a part of this study, we want you to know about 
the study.  You may choose not to be part of this study.  No health care will be withheld for your 
child should you choose not to be part of the study.  Your child will still receive the standard TB 
treatment used at this clinic / hospital.  
This is a consent form.  It gives you information about this study.  The study staff will talk with 
you about this information.  You are free to ask questions about this study at any time.  If you 
agree to allow your child to take part in this study, you will be asked to sign this consent form.  
You will get a copy to keep. 
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Why is this study being done? 
The purpose of this study is to evaluate the absorption of antituberculosis medicines in children 
with tuberculosis, both with and without HIV infection.  We will also examine whether factors 
such as malnutrition, liver disease or the presence of tuberculosis lymph nodes in the abdomen 
affect the absorption of antituberculosis medicines, their toxicity or their ability to cure 
tuberculosis. 
What will happen to my child and what will I have to do if my child is in this study? 
If you decide to allow your child to take part in this study a number of investigations will be done.  
These will help us determine whether your child has HIV infection, how serious the infection is, 
whether he/she is malnourished, and whether there are signs of liver damage.  We will also 
evaluate the function of the immune system by counting certain of the white cells in the blood.  
The absorption of the antituberculosis medicines will be studied by placing a needle in a vein 
and taking a small amount of blood 4 times during each of the two investigations.  The amount of 
the medicine in the blood will then be measured.  The test will be repeated about 2 months after 
the treatment of tuberculosis was started to see whether improvement in nutrition and the 
tuberculosis has made any difference to the absorption of the medicines.  All of the above 
investigations will mean taking approximately 3 teaspoonfuls of blood from your child. 
An X-ray of the chest and special X-ray of the abdomen will also be taken to evaluate the spread 
of tuberculosis in the body.  Your child's stool will also be examined for worms and signs of poor 
ability to absorb food or the antituberculosis medicines.  The urine will be examined regularly for 
signs of disease. 
If the diagnosis of tuberculosis has not been established the stomach juice will be withdrawn 
through a tube on two successive mornings and the throat will be aspirated to try and grow, or 
see, the tuberculosis germ. 
Your child will be examined for signs of poor nutrition once every month and your child will be 
examined every week for signs of toxicity caused by the antituberculosis medicines and a blood 
test to evaluate liver damage due to antituberculosis treatment will be done once a week for the 
first month of treatment and thereafter once a month until your child is discharged from hospital.  
This test requires about half a teaspoonful of blood.  
Two months and six months after admission to Brooklyn Hospital some of the blood tests will be 
repeated.  These include those for the evaluation of nutrition, immunity and liver damage.  These 
tests will require about 2 teaspoonfuls of blood.  The X-ray studies of the chest will be repeated 
2 months, 4 months and 6 months after starting tuberculosis treatment.  The X-ray of the 
abdomen will be repeated 4 months after starting treatment.  
After 6 months treatment stomach juice and the throat will again be aspirated to confirm that 
your child's tuberculosis really has been cured. 
 
Follow up visits 
After discharge from Brooklyn Hospital you will be given an appointment to bring your child back 
to either Tygerberg Children's Hospital or the Red Cross Children's Hospital eighteen months 
  69 
after the start of antituberculosis treatment.  During this visit the chest X-ray and the blood tests 
to evaluate nutrition, immunity and liver damage will be repeated.  These tests will also require 
about 2 teaspoonfuls of blood.  A stool specimen will again be examined for worms and for signs 
of failure to absorb foods.  
How many children will take part in the study? 
About 100 children will be enrolled in the study. 
How long will your child be in the study? 
Your child will be in the study for eighteen months after starting antituberculosis treatment.  If 
possible we would also like to follow your child up for a further three years to evaluate any long-
term problems that might be caused by tuberculosis and antituberculosis treatment, but we 
understand that this might be difficult for you. 
Why would the doctor take my child / baby off this study early? 
The study doctor may need to take your child/baby off the study early without your permission if: 
The study is cancelled by the site‟s Ethics Committee (the committee that watches over the 
safety and rights of research subjects). 
A Data Safety Monitoring Board (DSMB) recommends that the study be stopped early (A DSMB 
is an outside group of experts who monitor the study). 
Your child/baby is not able to attend the study visits as required by the study. 
The study doctor decides that it is harmful for you child/baby to continue in the research study. 
What are the risks of the study? 
Adverse reactions to TB medication are relatively rare, but in some patients they may be severe.  
If your child/baby experience any of the side effects described below you must let the study 
doctor or nurse know immediately. 
The side effects from the TB medication that you must report to the doctor or study nurse are: 
skin rash, blurred or changed vision, flu-like symptoms and fever for more that 3 days, stomach 
ache and upset, nausea and vomiting, lack of appetite, joint aches, bruises, dizziness, tingling 
and numbness around the mouth, tingling sensation in the hands and feet.  One of the TB drugs, 
Rifampicin, that your child/baby will receive, will colour the urine, sweat and tears orange. 
Are there benefits to taking part in this study? 
If your child/baby takes part in this study, there may be a direct benefit to your child/baby, but no 
guarantee can be made.  It is also possible that your child/baby may receive no benefit from 
being in this study.  Information learned from this study may help other children and babies who 
have HIV and TB infection or TB without HIV-infection. 
What other choices does my child/baby have besides this study? 
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Instead of being in this study you have the choice of TB treatment available to your child/baby at 
this hospital / clinic.  Please talk to your doctor about these and other choices available to your 
child/baby. Your doctor will explain the risks and benefits of these choices.  
Please also note that specific treatment for HIV (that is anti-retroviral drugs like AZT) are NOT 
available in the public hospitals but can be bought privately. 
What about confidentiality? 
Efforts will be made to keep your child‟s/baby‟s personal information confidential, however we 
cannot guarantee absolute confidentiality.  Your child‟s/baby‟s personal information may be 
disclosed if required by law.  On our study record we will use codes instead of your 
child‟s/baby‟s name.  Only the study staff will know these codes.  The study workers will not give 
out any information about your child/baby without written consent from you.  Your family‟s 
privacy will be respected.  The public health authorities will be notified as usual if your child/baby 
has TB.  Any publication of this study will not use your child‟s/baby‟s name or identify your 
child/baby personally. 
Your child‟s/baby‟s study records may be inspected by the South African Department of Health, 
study staff, study monitors, and drug companies supporting this study.  The study records will be 
kept separate from the normal medical records. 
What are the costs to me? 
There is no cost to you for the medication, study visits or laboratory tests.  All medical care will 
be provided by the study doctor.  
Will I receive any payment? 
We will re-imburse you transportation money to enable you to attend the hospital or clinic. 
What happens if my child/baby is injured? 
If your child/baby is injured as a result of being in this study, your child/baby will be given 
immediate treatment for his/her injuries at no cost to you. 
What are my rights and my child's rights as a research subject? 
Participation in this study is completely voluntary.  You may choose not to allow your child/baby 
to take part in this study or take your child/baby out of the study at any time.  Your child/baby will 
be treated the same no matter what you decide, there will be no penalty. 
We will tell you about new information from this or other studies that may affect your 
child‟s/baby‟s health, welfare or willingness to stay in this study.  If you want the results of the 
study, let the study staff know 
What do I do if I have questions or problems? 
For questions about this study or a research-related injury, contact either: 
Prof Peter Donald: Tel: 021/938-9506 or Prof Gregory Hussey: Tel: 021/685-4103 
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SIGNATURE PAGE 
THE PHARMACOKINETICS AND TOXICITY OF ANTITUBERCULOSIS AGENTS AND 
OTHER CO-ADMINISTERED DRUGS IN CHILDREN, WITH AND WITHOUT HIV INFECTION 
AND THEIR RELATIONSHIP TO NUTRITIONAL STATE AND TO THE NAT2 ACETYLATOR 
GENOTYPE AND PHENOTYPE. 
If you have read this consent form (or had it explained to you), all your questions have been 
answered and you agree to take part in this study, please sign your name below. 
       
Participant‟s Name (print) 
             
Participant‟s Mother or Father     Legal Guardian‟s Signature and Date 
or Legal Guardian(As appropriate)(print) 
             
Study Staff Conducting     Study Staff Signature and Date 
Consent Discussion (print)  
             
Witness‟ Name (print)     Witness‟s Signature and Date 
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Consent by a parent or legal guardian that the HIV status of their child may be 
determined. 
Title of the study:  
THE PHARMACOKINETICS AND TOXICITY OF ANTITUBERCULOSIS AGENTS AND 
OTHER CO-ADMINISTERED DRUGS IN CHILDREN, WITH AND WITHOUT HIV INFECTION 
AND THEIR RELATIONSHIP TO NUTRITIONAL STATE AND TO THE NAT2 ACETYLATOR 
GENOTYPE AND PHENOTYPE. 
As explained in the patient information document it is uncertain whether it is necessary to treat 
children with HIV infection and tuberculosis for 6 months or 9 months.  It is therefore important 
for the researchers to know whether or not your  child is infected with the HI-virus.  We therefore 
request your permission to allow us to determine the HIV status of your child.  To do this a single 
sample of blood of about 2,5 ml, or half-a-teaspoonful, will be drawn by inserting a needle into 
one of the veins in your child's arm.  You will be informed of the results of the test as soon as 
they become available.  The results will be known only to the researchers who are conducting 
the study.  When the results are available you will receive further counseling and should the 
result indicate that your child is HIV-infected you will be referred to the infectious diseases clinic 
for advice and further management. 
Consent 
I, the undersigned parent (or guardian) of (give name of child):    
 , 
herewith give permission that the HIV-status of my child may be determined. 
Signature of parent or legal guardian giving consent:       
Parent or legal guardian's name in block letters:       
 Date:       
Signature of witness confirming consent:       
  
Name of witness in block letters:        
 Date:       
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INGELIGTE TOESTEMMING 
 
PEDIATRIESE HIV/TB NAVORSINGKONSORTIUM 
UNIVERSITEIT VAN KAAPSTAD 
EN 
UNIVERSITEIT VAN STELLENBOSCH 
DIE FARMAKOKINETIKA EN TOKSISITEIT VAN ANTITUBERKULOSE-MIDDELS EN ANDER 
SAAMTOEGEDIENDE MIDDELS IN KINDERS MET TUBERKULOSE MET OF SONDER MIV-
INFEKSIE EN HULLE VERWANTSKAP MET DIE VOEDINGSTATUS EN DIE NAT2-
ASETILATOR GENOTIPE EN FENOTIPE 
Verkorte titel vir die studie: Die farmakokinetika van antituberkulosemiddels in kinders 
met tuberkulose met en sonder MIV-infeksie. 
 
Inleiding 
TB en MIV-infeksie is ernstige gemeenskapsgesondheid probleme in Suid Afrika. Wanneer hulle 
saam voorkom word die uitkoms van beide toestande slegter. Daar is ook onsekerheid oor wat 
is die beste dosisse van antituberkulose medisyne wat in kinders gegee behoort te word, beide 
in die met, en sonder MIV-infeksie. Aan die een kant mag te min medisyne onvoldoende wees 
om die tuberkulose kieme dood te maak en mag dus tot die opflikkering van tuberkulose lei; aan 
die anderkant mag te veel medisyne tot toksisiteit lei.  Dit is ook moontlik dat kinders met MIV-
infeksie meer vatbaar mag wees vir die toksiese newe-effekte van antituberkulose medisyne. 
Tydens hierdie studie sal ons die wyse waarop kinders antituberkulose medisyne absorbeer en 
verteer meet en kyk of MIV-infeksie en sy komplikasies, wanvoeding of tuberkulose self enige 
uitwerking het op die manier hoe kinders met tuberkulose antituberkulose middels absorbeer en 
daarop reageer.   
Hierdie studie word deur Bristol-Myers Squibb – “Secure the future”-Stigting geborg. 
Die geneeshere in beheer van die studie by hierdie lokaal is Professor Peter Donald van die 
Departement Pediatrie en Kindergesondheid van die Fakulteit Gesondheidswetenskappe, 
Universiteit van Stellenbosch en Professor Gregory Hussey van die Departement van Kinder- en 
Adolesente-gesondheid van die Fakulteit van Gesondheidswetenskappe van die Universiteit van 
Kaapstad. 
Voordat u besluit of u wil hê dat u kind/baba moet deelneem aan die studie, wil ons eers graag 
hê dat u van die studie moet weet. U mag verkies dat u kind nie aan die studie deel neem nie. 
Geen gesondheidsorg sal vir u kind weerhou word nie al sou u besluit om nie aan die studue 
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deel te neem nie.U kind sal dan steeds die gewone  TB-behandeling onvang wat by hierdie 
kliniek/hospitaal gebruik word. 
Hierdie is „n toestemmingsvorm. Dit gee u inligting in verband met die studie. Die 
studiepersoneel sal met u gesels oor die inligting. Dit staan u vry om te eniger tyd vrae oor die 
studie te vra. Indien u instem dat u kind aan die studie mag deelneem, sal u gevra word om die 
toestemmingsvorm te teken. U sal „n afskrif kry wat u kan hou. 
 
Hoekom word hierdie studie gedoen? 
Die doel van hierdie studie is om die absorpsie van antituberkulose medisyne in kinders met 
tuberkulose, beide met, of sonder, MIV infeksie te bepaal. Ons sal ook nagaan of faktore soos 
wanvoeding, lewersiekte of die teenwoordigheid van tuberkulose kliere in die buik die absorpsie 
van antituberkulose middels, hulle toksisiteit of hulle vermoë om tuberkulose te genees, 
beïnvloed. 
 Wat sal met my kind gebeur en wat word van my verwag as my kind deelneem aan 
hierdie studie? 
Sou u besluit om u kind aan hierdie studie te laat deelneem sal 'n aantal ondersoeke gedoen 
word. Hierdie ondersoeke sal vir ons help bepaal of u kind MIV-infeksie het, hoe ernstig die 
infeksie is, of hy/sy wangevoed is en of daar enige tekens van lewerskade is. Ons sal ook die 
funksie van die immuunsisteem nagaan deur sekere witselle in die bloed te tel. Die absorpsie 
van die antituberkulose medisyne sal bepaal word deur 'n naald in 'n aar te plaas en dan 
daardeur vierkeer 'n klein hoeveelheid bloed te neem. Die hoeveelheid medisyne in die bloed 
monsters sal dan bepaal word. Die toets sal na twee maande herhaal word om te kyk of 'n 
verbetering in voeding of die behandeling van tuberkulose enige verskil in die absorpsie van die 
middels te weeg gebring het. Al hierdie ondersoeke beteken dat daar om en by 3 teelepelsvol 
bloed van u kind geneem sal moet word. 
'n X-straal ondersoek van die borskas en 'n spesiale ondersoek met klankgolwe van die buik sal 
ook gedoen word om die verspreiding van tuberkulose in die liggaam te beoordeel. U kind se 
stoelgang sal ook ondersoek word vir wurms en tekens van 'n swak vermoë om voedsel te 
absorbeer. Die uriene sal gereeld nagegaan word vir tekens van siekte. 
Indien die diagnose van tuberkulose nog nie bevestig is nie, sal maagsappe en keel aspirate 
twee agerteenvolgende oggende getrek word om die tuberkulose kiem te probeer sien of kweek. 
U kind sal ook een keer elke maand ondersoek word vir tekens van wanvoeding en u kind sal 
ook elke week vir tekens van toksisiteit as gevolg van die tuberkulose medisyne ondersoek 
word. Daar sal elke week vir die eerste maand van behandeling en maandeliks daarna, terwyl u 
kind in hospitaal behandel word, 'n bloedtoets gedoen word om moontlike lewerskade as gevolg 
van die tuberkulose behandeling vroegtydig op te spoor. Hierdie toets benodig ongeveer 'n 
halwe teelepelvol bloed. 
Na 2 maande en 6 maande na toelating tot Brooklyn Hospitaal sal sekere van die bloed toetse 
herhaal word. Hierdie toetse sluit in dié vir die evaluasie van voeding,  immuniteit en lewerskade. 
Ongeveer twee teelepels bloed word elke slag benodig vir hierdie toetse. Die X-straal ondersoek 
van die borskas sal 2 maande, 4, 6 en 18 maande na die begin van behandeling herhaal word. 
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Die klankgolf X-straal ondersoek van die buik sal 4 maande na die begin van behandeling 
herhaal word. 
Na 6 maande van behandeling sal 'n maagsap en keel aspiraat weer verkry word en sal daar 
weer vir die tuberkulose kiem gesoek word om te bevestig dat u kind se tuberkulose werklik 
genees is. 
 
Opvolg Besoeke 
Na ontslag uit Brooklyn Hospitaal sal u 'n afspraak kry om u kind na die Tygerberg 
Kinderhospitaal of die Rooikruis Kinderhospitaal te bring 18 maande na die begin van 
tuberkulose behandeling. Tydens hierdie besoek sal die X-straal ondersoek van die borskas en 
die buik herhaal word as ook die bloed toetse om u kind se voeding en immuniteit te bepaal en 
ook om te kyk of daar enige tekens van lewerskade is. Hierdie toetse sal ook om en by twee 
teelepelsvol bloed benodig. 'n Stoelgang sal ook weer ondersoek word vir wurms en tekens van 
gebrekkige absorpsie van voedingstowwe. 
Hoeveel kinders sal aan die studie deelneem? 
Ongeveer 100 kinders sal aan die studie deelneem. 
Hoe lank sal my kind/baba in die studie wees? 
U kind sal in die studie wees vir 18 maande na die begin van tuberkulose behandeling. Indien 
moontlik sal ons u kind vir 'n verdere drie jaar wil opvolg, om enige langtermyn probleme wat 
verband mag hê met die behandeling van tuberkulose te identifiseer, maar ons besef dat dit dalk 
vir u moeilik sal wees.. 
Vir watter redes sal die dokter my kind/baba vroeër uit die studie haal? 
Die studiedokter mag moontlik u kind/baba vroeër uit die studie verwyder sonder u toestemming 
as: 
 Die studie deur die Etiese Komitee (die komitee wat toesig hou oor die veiligheid en 
regte van die studiepasiënte) gekanselleer word. 
 „n Dataveiligheid Toesighoudende Raad (DVTR) aanbeveel dat die studie vroegtydig 
gestaak moet word. (Die DVTR is „n buitegroep van kundiges wat die studie dophou). 
 U kind/baba nie die studiebesoeke kan nakom soos deur die studie verlang nie. 
 Die studiedokter besluit dat dit vir u kind/baba skadelik is om met die studie voort te 
gaan. 
 Wat is die risiko’s van die studie? 
Newe-effekte (nadelige gevolge) op TB-behandeling is relatief skaars, maar dit kan erg 
wees in sommige pasiënte. Indien u kind/baba enige vorm van die newe-effekte 
hieronder beskryf, ervaar, moet u die studiedokter of studieverpleegkundige onmiddellik 
laat weet. 
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Die newe-effekte van die TB-medikasie wat u aan die studiedokter of 
studieverpleegkundige moet rapporteer is: 
 
Veluitslag, vae of veranderde visie (oë kyk snaaks), griepagtige simptome en koors vir 
meer as 3 dae, maagpyne en diaree, naarheid en braking, verlies aan eetlus, 
gewrigspyne (pyne in litte), kneusplekke, duiseligheid, speldprikgevoel en verlies van 
gevoel om die mond, naalde-en-spelde gevoel in die hande en voete. Een van die anti-
TB-middels wat u kind/baba gaan kry, rifampisien, gaan die uriene, sweet en trane „n 
oranje kleur gee. 
 Is daar voordele om deel te neem aan die studie? 
 
As u kind/baba aan die studie deelneem, kan daar „n direkte voordeel vir u kind/baba 
wees, maar geen waarborg kan hiervoorgegee word nie. Dit is ook moontlik dat u 
kind/baba geen voordeel van deelname aan die studie sal hê nie. Inligting wat met die 
doen van hierdie studie verkry word, kan ander kinders en babas wat MIV- en TB-
infeksie, of net TB sonder MIV-infeksie het, help. 
 Watter ander keuses behalwe hierdie studie is vir my kind/baba beskikbaar? 
 
In plaas daarvan om aan hierdie studie aan hierdie studie deel te neem, het u die keuse 
van TB-behandeling vir u kind/baba wat by hierdie hospitaal/kliniek beskikbaar is. Praat 
asseblief met u dokter oor hierdie en ander keuses wat vir u kind/baba beskikbaar is. U 
dokter sal die voor- en nadele van hierdie keuses aan u verduidelik. 
 
Let asseblief ook daarop dat spesifieke behandeling vir MIV (dit is anti-retroviralemiddels 
soos AZT) tans nie in die staatshospitale beskikbaar is nie, maar wel privaat aangekoop 
kan word. 
 Wat van vertroulikheid? 
 
Ons sal moeite doen om u kind/baba se persoonlike inligting vertroulik te hou, maar ons 
kan nie absolute vertroulikheid waarborg nie. U kind/baba se persoonlike inligting kan 
geopenbaar word as die wet dit vereis. Op ons studierekords sal ons kodes gebruik in 
plek van u kind/baba se naam. Slegs die studiepersoneel sal hierdie kodes ken. Dit 
studiepersoneel sal geen inligting oor u kind/baba verstrek sonder u skriftelike 
toestemming nie. U gesin se privaatheid sal gerespekteer word. Die 
gemeenskapsgesondheids-owerhede sal, soos gebruiklik, in kennis gestel word indien u 
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kind/baba TB het. Enige publikasie voortspruitend uit hierdie studie sal nie die naam van 
u kind/baba verstrek nie, of u kind/baba persoonlik identifiseer nie. 
 
U kind/baba se studierekords kan deur die Suid-Afrikaanse Departement van 
Gesondheid, studiepersoneel, studiemoniteerders en farmaseutiese firmas wat die studie 
finansieel ondersteun, ondersoek word. Die studierekords sal apart van die normale 
mediese lêers gebêre word. 
 Wat sal dit my kos? 
 
Daar is geen koste vir u ten opsigte van die medikasie, studiebesoeke of 
laboratoriumondersoeke nie. Alle mediese sorg sal deur die studiedokter voorsien word. 
 Sal ek enige betaling ontvang? 
 
Ons sal u vervoerkoste aan u terugbetaal om dit vir u moontlik te maak om die 
hospitaal/kliniek by te woon. 
 Wat gebeur as my kind/baba beseer word 
 
Indien u kind/baba beseer word as gevolg van deelname aan die studie, sal u kind/baba 
onmiddelike behandeling vir sy/haar besering ontvang. 
 Wat is my regte en my kind/baba se regte as ‘n navorsingonderwerp? 
 
Deelname aan die studie is heeltemal vrywillig. U mag kies om nie u kind/baba aan die 
studie te laat deelneem nie, of u kind/baba te eniger tyd uit die studie te onttrek. U 
kind/baba sal dieselfde behandeling ontvang, dit maak nie saak wat u sou besluit – daar 
sal geen straf wees nie. 
 
Ons sal vir u op hoogte hou van enige nuwe informasie vanuit hierdie of ander studies wat u 
kind/baba se gesondheid mag affekteer of u bereidwilligheid om nog deel te neem aan hierdie 
studie. Indien u belangstel in die uitslae van hierdie studie stel asseblief vir die studie personeel 
in kennis. 
 
Wat moet ek maak as ek vrae of probleme het? 
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In verband met vrae ten opsigte van die studie of 'n navorsingsverwante beseering bel vir Prof 
PR DonaldTel: 021/9589506 of Prof G Hussey: tel: 021/685-4103 
  
 
HANDTEKENINGBLADSY 
 
DIE FARMAKOKINETIKA EN TOKSISITEIT VAN ANTITUBERKULOSE-MIDDELS 
EN ANDER SAAMTOEGEDIENDE MIDDELS IN KINDERS MET TUBERKULOSE 
MET OF SONDER MIV-INFEKSIE EN HULLE VERWANTSKAP MET DIE 
VOEDINGSTATUS EN DIE NAT2-ASETILATOR GENOTIPE EN FENOTIPE 
 
As u hierdie toestemmingsvorm gelees het (of dit aan u verduidelik is), al u vrae beantwoord is 
en u instem om deel te neem aan die program, teken asseblief u naam hieronder . 
_________________________ 
Deelnemer se naam(drukskrif) 
__________________________  _____________________________ 
Deelnemer se Moeder, Vader of  Wettige Voog se handtekening  
Wettige Voog(soos Toepaslik) in              
drukskrif 
                                                                 Datum ……………………………….. 
 
__________________________  _____________________________ 
Studie Personeel wat Toestemmings Studie Personeel se Handtekening 
Bespreking Behartig (drukskrif)   
                                                                 Datum………………………………. 
__________________________  _____________________________ 
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Getuie se Naam(drukskrif)   Getuie se Handtekening  
                                                                 Datum………………………………… 
 
Toestemming deur ‟n ouer of wettige voog dat die MIV-status van hulle kind bepaal mag word. 
Titel van die studie: DIE FARMAKOKINETIKA EN TOKSISITEIT VAN ANTITUBERKULOSE-
MIDDELS EN ANDER SAAMTOEGEDIENDE MIDDELS IN KINDERS 
MET TUBERKULOSE MET OF SONDER MIV-INFEKSIE EN HULLE 
VERWANTSKAP MET DIE VOEDINGSTATUS EN DIE NAT2-
ASETILATOR GENOTIPE EN FENOTIPE 
Soos in die pasiënt informasie dokument verduidelik, is dit onseker of kinders met MIV-infeksie 
en tuberkulose vir 6 maande of 9 maande behandel moet word. Dit is dus belangrik vir die 
navorsers om te weet of u kind met die MI-virus geïnfekteer is al dan nie. Ons versoek dus u 
toestemming om ons toe te laat om u kind se MIV-status te bepaal. Om dit te doen moet ‟n 
enkele bloedmonster van 2,5 ml, of omtrent ‟n halwe teelepel vol, geneem word deur ‟n naald in 
een van die are in u kind se arm te plaas. U sal ingelig word oor die uitslag van die toets sodra 
dit beskikbaar word. Die uitslag sal slegs bekend wees aan die navorsers verantwoordelik vir die 
uitvoering van die studie. Beide voor en na die toets sal u toepaslike berading ontvang en indien 
die uitslag van die studie daarop sou dui dat u kind met die MIV geinfekteer is, sal u verwys 
word na die Infeksie Siekte Kliniek vir raad en hulp. 
Toestemming 
Ek, die ondergetekende ouer (of wettige voog) van (gee naam van die kind): 
---------------------------------------- gee hiermee toestemming dat die MIV-status van my kind bepaal 
mag word. 
Handtekening van die ouer of wettige voog wat toestemming gee: 
 ------------------------------------------------- 
Naam van ouer of voog in blokletters: ------------------------------------------------- 
 Datum: ------------------------------- 
Handtekening van getuie wat die toestemming bevestig: 
 ------------------------------------------------- 
Naam van getuie in blokletters: ------------------------------------------------- 
 Datum: ------------------------------- 
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Pharmacokinetic study Xhosa consent form:Version 2  
 
BMS: Khusela Ixesha Elizayo  
INtlangano yamaQumrhu oPhando ngesifo sephepha (TB) ne-HIV ebantwaneni    
IYunivesithi yaseKapa / iYunivesithi yaseStellenbosch  
THE PHARMACOKINETICS AND TOXICITY OF ANTITUBERCULOSIS AGENTS AND 
OTHER CO-ADMINISTERED DRUGS IN CHILDREN, WITH AND WITHOUT HIV INFECTION 
AND THEIR RELATIONSHIP TO NUTRITIONAL STATE AND TO THE NAT2 ACETYLATOR 
GENOTYPE AND PHENOTYPE. 
Isihloko esifutshane: I-pharmacokinetics kunye netyhefu eyenziwa sisifo sephepha 
ebantwaneni abanayo nabangenayo i-HIV.    
Amaxwebhu eMvume yolwazi  
Intshayelelo 
I-HIV/AIDS kunye nesifo sephepha zezona zifo eziyigxaki yempilo e-Mzantsi Afrika. Xa ezi zifo 
zivela zombini zenzelana isiphumo esibi kumntu ogulayo. Akuqinisekwanga ukuba leliphi iyeza 
elinganceda kakhulu kulawo akhoyo okunyanga isifo sephepha (antituberculosis medicines), 
angasetyenziswa ebantwaneni abanesifo sephepha, nabo abanayo nabangenayo i-HIV.  
Kwelinye icala kungenzeka ukuba xa ulisebenzisa kancinci eli yeza lingathi lingoneli ekubulaleni 
intsholongwane yesifo sephepha, lonto ingenza ukuba isifo sephepha singapheli emzimbeni; 
kwelinye icala  xa ulisebenzisa kakhulu eli yeza lingenza ubenetyhefu emzimbeni.   Kungenzeka 
ukuba abantwana abaphethwe yi-HIV bangabasengozini yetyhefu eyenziwa sisiphumo 
esisesinye ngaphandle kweso besijongiwe ngenxa yamayeza anyanga isifo sephepha 
(antituberculosis medicines).  Ngexesha  lesi sifundo sizakwenza umlinganiselo wendlela 
abantwana abaphethwe sisifo sephepha abathi baphatheke ngayo nenguqulelo emizimbeni 
yabo ngala mayeza okunyanga isifo sephepha  kwakunye nokuvavanya i- HIV nokungatyi 
kakuhle kunye nesifo sephepha, bafumana eziphi iziphumo ezingezinye ngaphandle kwezo 
bezijongiwe ngenxa yamayeza e-TB. 
Esi sifundo sixhaswe ngemali ngabakwa Bristol Myers Squibb – Secure the Future Foundation.  
OoGqirha abaphetheyo kwesi sifundo kule ndawo ngaba: Professor Peter Donald of 
theDepartment of Paediatrics and Child Health of the Faculty of Health Sciences, the University 
of Stellenbosch and Professor Gregory Hussey of the School of Child and Adolescent Health. 
University of Cape Town. 
Ngaphambi kokuba uvumele umntwana wakho ukuba athathe inxaxheba kwesi sifundo, sifuna 
ukukwazisa ngesi sifundo sisonke.  Kuxhomekeke kuwe ukuba uyafuna okanye awufuni 
ukuthatha inxaxheba kuso.  Akusayi kurhoxiswa lunyango  kumntwana wakho xa ungafuni 
ukuthatha inxaxheba kwesi sifundo.  Umntwana wakho uza kukwazi ukuya eklinikhi okanye  
esibhedlele ukuze afumane unyango lwesifo sephepha (TB).  
Lena yifomu yesivumelwano.  Ikunika ulwazi ngesi sifundo.  Iqela labasebenzi kolu fundo baza 
kuthetha nawe ngolwazi nangezinto ofuna ukuzazi.  Ungabuza noba yintoni, noba kunini ukuba 
awuqinisekanga ngesi sifundo.  Ukuba uyavuma ukuba umntwana wakho athathe inxaxheba 
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kwesi sifundo, uzakucelwa ukuba usayine ifomu yesivumelwano.  Uzakufumana ikopi oza 
kuyigcina.  
Kutheni kusenziwa esi sifundo? 
Injongo yesi sifundo kukuvavanya ukuthabatheka okanye indlela athi asebenze ngayo amayeza 
okunyanga isifo sephepha ebantwaneni abaphethwe sesi sifo, nabaphethwe yintsholongwane 
eyosulelayo i-HIV.  Siya kuphinda sihlole iimeko ezifana nokungabinako ukutya okwaneleyo 
okunempilo okanye ukungondleki, isifo sesibindi okanye ubukho besifo sephepha buthi 
buchaphazele ukutsaleka kwamayeza esifo sephepha, ubutyhefu bawo okanye indlela athi 
akwazi ngayo ukunyanga isifo sephepha. 
Kuzakwenzeka ntoni emntwaneni wam, yintoni ekufanele ndiyenze xa umntwana ekwesi 
sifundo? 
 
Ukuba ugqibe ekubeni umntwana wakho makathathe inxaxheba kwesi sifundo, kuza kwenziwa 
uluhlu lophando.  Olu phando luza kusinceda ukubona  ukuba umntwana wakho akanayo na i- 
HIV, nokubona ukuba isifo simphethe kangakanani, okanye akondlekanga, kwakunye nokuba 
kukho iimpawu zesibindi esonakeleyo.  Siza kubala  inani leeseli ezimhlophe egazini ukwenzela 
ukuvavanya obungakanani bomlinganiselo asebenza ngayo amajoni omzimba.  Kuza kwenziwa 
isifundo ngokufunxwa kwamayeza anyanga isifo sephepha ngokufaka inaliti kumthambo wegazi, 
kutsalwe amaqabaza egazi kahlanu kwixhesha ngalinye kolu phando lubini.     Kuza kubalwa 
inani leyeza eliphakathi egazini.  Olu vavanyo luza kuphindwa emva kwenyanga ezine emva 
konyango lokuqala lwesifo sephepha ukwenzela ukubona ukuba awukho na umahluko obhetele 
kwisondlo, nokuba isifo sephepha senze  umahluko omngakanani ngeli xesha iyeza  lisebenza 
emzimbeni.  Lonke olu phando olungentla olwenziweyo luchaza ukuba kuza igazi 4-
elingangeetisipuni ezintathu kumntwana wakho.    
Kuza kuthathwa i-X-rayi  yesifuba kunye ne-X-rayi yodwa yesisu ukuvavanya ukuba isifo 
sephepha singene kangakanani emzimbeni.   Ituwa yomntwana wakho izakuhlolwa 
kukhangelwe impawu zeenthsulube kunye nokubona ukuba ukutya kutsaleka kakuhle na 
okanye akutsaleki okanye amayeza isifo sephepha ayatsaleka emzimbeni.   Umchamo uza 
kuhlolwa rhoqo ukujonga impawu zesifo. 
Ukuba uxilongo lwesifo sephepha alubonakali kuza kutsalwa incindi yesisu ngethumbu rhoqo 
kusasa intsuku zilandelelana, ukuzama ukhulisa, okanye ukubona intsholongwane yesifo 
sephepha.     
Umntwana wakho uzakuhlolwa rhoqo ngenyanga impawu zokuba utya kakuhle na, aphinde 
ahlolwe rhoqo ngeveki impawu zetyhefu eyenziwa ngamayeza esifo sephepha, kuphindwe 
kuhlolwe igazi ukwenzela ukubona ukuba isibindi sonakale kangakanani xa kunyangwa isifo 
sephepha kanye ngeveki, kwinyanga yokuqala, emva koko anganyangwa kubekanye 
ngenyanga ade akhutswe  esibhedlele. Kolu vavanyo kufuneka ihafu yetisipuni yegazi.  
Emva kwenyanga  ezine efikile esibhedlele sase-Brooklyn, ukuhlolwa kwegazi kuzakuphindwa.   
Oku kuquka uvavanyo lwendlela yokutya, ukungabinakusulelwa kwakho  zizifo ezithile 
nokonakalelwa sisibindi.  Kolu luvavanyo kufuneka itisipuni ezimbini zegazi. Ufundo lwe-X-ray 
yesifuba luza kuphindwa kwiinyanga ezimbini, ezine, ezintandathu emva kokuqalisa unyango 
lwesifo sephepha.  I-X-rayi yesisu iza kuphindwa kwiinyanga ezine emva kokuqalisa unyango 
lwesifo sephepha.   
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Emva kwenyanga ezimbini unyango lwencindi zesisu luza kuphindwa lenziwe ukuqinisekisa 
ukuba umntwana wakho unyangekile kwisifo sephepha. 
Olu fundo luza kwenziwa ngabantwana abangaphi ? 
Kuza kubhaliswa abantwana abangama-80 kwesi sifundo.  
Uzakuthatha ixesha elingakanani umntwana wakho ekwesi sifundo? 
Umntwana wakho uzakuhlala ixesha elingangeenyanga ezisithandathu emva kokuba  eqalile 
unyango lwesifo sephepha.   
Kutheni ugqirha eza kuthatha umntwana wam/usana lwam aluyekise kolu fundo 
kamsinyane? 
UGqirha wesi sifundo angakhawuleza amyekise umntwana wakho kolu fundo  ngaphandle 
kwemvume yakho xa:    
Ufundo luyekiswe yiKomiti ebizwa ngokuba yi-Ethics Committee (ikomiti ejonga ukhuseleko 
namalungelo ophando kwisifundo). 
I-Data Safety Monitoring Board (DSMB) iphakamise uluvo lokuba olu fundo luyekiswe 
kwangethuba (I-DSMB liqela langaphandle leengcaphephe ezongamele isifundo esithile). 
Umntwana wakho/ usana lwakho alukwazi ukufikelela kolufundo ngemini abizwe ngazo 
njengoko kufuneka njalo. 
Ugqirha wesifundo ubona ukuba umntwana wakho usengozini kolu fundo. 
Zeziphi iingozi kolu fundo? 
Ububi obenziwa ngamayeza okunyanga i-TB bunqabile kodwa kwezinye  izigulane kungaphuma 
iziphumo ezibi.  Ukuba umntwana wakho ufumana isiphumo esisesinye ngaphandle kweso 
besijongiwe nezichaziweyo ngezantsi, kufuneka wazise ugqirha wesifundo okanye umongikazi 
ngokukhawuleza 
Iziphumo ezizezinye ngaphandle kwezo bezijongiwe zokunyanga i-TB ezichaziweyo ngezantsi, 
kufuneka wazise ugqirha wesifundo okanye umongikazi wesifundo  ngokukhawuleza: 
irhashalala, ukubona mfiliba okanye ukungaboni ngale ndlela obubona ngayo ekuqaleni, 
iimpawu zefiva nokuba nefiva ngaphezu kweentsuku ezintathu, ukuphathwa sisisu okanye isisu 
esixuxuzelayo, isicaphucaphu, ukugabha, ukungacaceli ukutya, amalungu omzimba abuhlungu, 
ukugruzuka, isiyezi, ukuntlontlozela kunye nobundindisholo obujikeleze umlomo, ukuntlontlozela 
okuvakalayo ezandleni nasezinyaweni. Esinye seziyobisi ze-TB, i-Rifampicin, eza kunikwa 
umntwana wakho, iza kutshintsha umbala womchamo, wombilo kunye nenyembezi zibe-orenji. 
Ikhona na inzuzo efumanekayo kolu fundo?  
Ukuba umntwana wakho uthatha inxaxheba kolu fundo, umntwana wakho kungenzeka afumane 
uncedo olukhulu, kodwa oku akunakuqinisekiswa.   Kungenzeka ukuba umntwana wakho 
angafumani nto ngokuthatha kwakhe inxaxheba kwesi sifundo.  Ulwazi olufumaneke kwesi 
sifundo lunganceda abanye abantwana neentsana ezine-HIV kunye ne-TB okanye abane-TB 
kodwa bengenayo i-HIV.     
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Zeziphi ezinye izinto umntwana wam anokuzikhethela zona ngaphandle kolu fundo? 
Endaweni yokuthatha inxaxheba kolu fundo, umntwana wakho angakwazi ukufumana uncedo 
lokunyanga i-TB eklinikhi okanye esibhedlele.   Uyacelwa ukuba uthethe nogqirha wakho 
malunga noku kunye nezinto ongazenzayo ekuncedeni umntwana wakho.   Ugqirha wakho 
uyakuchazela kakuhle ngobungozi kunye nenzuzo ongayifumana kwesi sifundo       
Nceda uqaphele ukuba  unyango olujongene ne-HIV (i-anti-retroviral drugs enjenge- AZT)  
ayifumaneki ezibhedlela zoluntu kodwa ungakwazi ukuyithenga kwindawo zabucala zonyango.   
Ingaba oku kugcinwa kulihlebo? 
Kuya kwenziwa iinzame zokugcina ulwazi ngomntwana wakho luyimfihlo, kodwa 
asinokuqinisekisa ngokufihla olu lwazi     Ulwazi ngomntwana wakho luya kuvezwa xa lifunwa 
ngabomthetho.   Kwesi sifundo siza kusebenzisa iikhowudi endaweni legama lomntwana wakho.  
Ezi khowudi ziya kwaziwa ngabasebenzi abakolufundo kuphela.   Abantu  abasebenza  kwesi 
sifundo abanalungelo lokunika ulwazi olumalunga nomntwana wakho ngaphandle kwemvume 
yakho ebhalwe phantsi.      Imfihlo yosapho lwakho ihloniphekile. Iziphatha-mandla zempilo 
yoluntu ziya kwaziswa njengendlela eqhelekileyo ukuba umntwana wakho une-TB.  Upapasho 
lwesi sifundo alusayi kusebenzisa igama lomntwana wakho okanye kukhethwe umntwana/ 
usana lwakho ngenkqu. 
Iingxelo zomntwana/zosana lwakho ziyakuhlolwa liSebe loMzantsi Afrika lezeMpilo, abasebenzi 
kolu fundo, omnye umntu okwesi sifundo onikwe igunya lokuphatha abanye, kunye 
neenkampani zeziyobisi ezixhase olu fundo.  Iingxelo zesi sifundo ziya kugcinwa 
ngokwahlukeneyo kwiingxelo eziqhelekileyo zonyango. 
Ndiza kuhlawula imali engakanani? 
Ayikho imali ozakuyihlawula xa usiza kwesi sifundo, kunye namayeza okanye nohlolo olwenziwa 
kwindlu esetyenziswa ekwenzeni uphando nemilingo yeenzululwazi.  Lonke unyango luya 
kunikezwa ngugqirha wesifundo. 
Ingaba ukhona umvuzo endizakuwufumana?  
Imali yesithuthi oyisebenzisileyo xa usiza eklinikhi okanye esibhedlele siza kuyibuyisa.   
Kuza kwenzeka ntoni xa umntwana wam/usana lwam lonzakele?   
Ukuba umntwana/ usana lwakho lwenzakele ekule nkqubo yesi sifundo, uya kufumana unyango 
olukhawulezileyo ngaphandle kwentlawulo.  
Ngawaphi amalungelo endinawo mna kunye nomntwana wam ngokuthatha inxaxheba 
kwesi sifundo? 
Ukuthatha inxaxheba kwesi sifundo ukwenza ngokuzithandela kwentliziyo yakho. 
Ungangamvumeli umntwana wakho ukuba athathe inxaxheba kolu fundo, okanye ungamkhupha 
nokuba kunini umntwana wakho kolu fundo. Umntwana/ usana lwakho luya kufumana unyango 
olufanayo, nokuba ufike kwesiphi isigqibo, akusayi kubakho sohlwayo. 
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Sizokuxelela xa kukhona ulwazi olutsha olufikileyo, nolunye ufundo olunesiphumo esifana nesi 
olungaphazamisa impilo yomntwana wakho, ezentlalo-ntle okanye ukuvuma ukusebenzisana 
kwesi sifundo. Xa ufuna iziphumo zesi sifundo, kufuneka wazise abasebenzi kwesi sifundo. 
Ndenze ntoni xa ndinemibuzo okanye iingxaki? 
Mayelana nemibuzo ngesi sifundo okanye uphando malunga nokwenzakala, dibana  no:  
Prof Peter Donald: Ifoni:  (021) 938-9506 okanye  Prof Gregory Hussey:  Ifoni: (021) 685-
4103 
IPHEPHA LOKUSAYINA  
THE PHARMACOKINETICS AND TOXICITY OF ANTITUBERCULOSIS AGENTS AND 
OTHER CO-ADMINISTERED DRUGS IN CHILDREN, WITHAND WITHOUT HIV INFECTION 
AND THEIR RELATIONSHIP TO NUTRITIONAL STATE AND TO THE NAT2 ACETYLATOR 
GENOTYPE AND PHENOTYPE. 
Ukuba uyifundile le fomu yesivumelwano (okanye ucaciseliwe okuqhubekayo kule fomu), yonke 
imibuzo yakho iphenduliwe kwaye uyavuma ukuthatha inxaxheba kwesi sifundo, nceda usayine 
igama lakho ngezantsi. 
            
Igama loMthath‟inxaxheba ( bhala ngonoobumba abangadityaniswanga)  
            
Igama likaMama okanye likaTata  womthathi-nxaxheba   Umgcini  
okanye Umgcini Osemthethweni (Ngokubekiweyo ) Osemthethweni   Sayina kunye 
Nomhla 
(bhala ngonoobumba abangadityaniswanga ) 
______________________________________________________________ 
Umsebenzi oQhuba uFundo    msebenzi okolu fundo:  Sayina kunye nomhla   
Imvume yengxoxo (bhala ngonoobumba abangadityaniswanga)  
______________________________________________________________ 
Igama lengqina        Isandla sengqina nomhla 
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Imvume eyenziwa ngumzali okanye umgcini womntwana ngokusemthethweni malunga 
nokwaziswa kobume be-HIV emntwaneni wabo. 
Isihloko sofundo:  
THE PHARMACOKINETICS AND TOXICITY OF ANTITUBERCULOSIS AGENTS AND 
OTHER CO-ADMINISTERED DRUGS IN CHILDREN, WITH AND WITHOUT HIV INFECTION 
AND THEIR RELATIONSHIP TO NUTRITIONAL STATE AND TO THE NAT2 ACETYLATOR 
GENOTYPE AND PHENOTYPE. 
Njengoba bekuchaziwe encwadini yolwazi yesigulana ukuba akuqinisekwanga ukuba ikhona na 
imfuneko yokunyanga umntwana one-HIV kunye nesifo sephepha ixesha elingangeenyanga 
ezintandathu okanye ezilithoba. Kubalulekile ukuba abaphandi   baqinisekise ukuba umntwana 
wakho akanayo okanye unayo intsholongwane ye-HIV      Ngenxa yoko, siyakucela ukuba 
usinike imvume sibone imeko ye-HIV emntwaneni wakho.  Sizakutsala ngenaliti igazi 
elingumlinganiselo ongange-2,5 ml okanye ihafu yetisipuni egcweleyo kumthambo wegazi 
osengalweni yomntwana wakho.  Uya kunikwa iziphumo zokuhlolwa xa sezikhona.   Iziphumo 
ziya kwaziwa ngumphandi   yedwa  oqhuba olu fundo. Xa sezikhona iziphumo uzakufumana 
uncedo ukuba iziphumo zithi umntwana wakho une-HIV uya kuthunyelwa kwiklinikhi yezifo 
ezosulelayo ukuze ufumane iingcebiso nolawulo olungolunye loku. 
Imvume 
Mna, mzali osayine ngezantsi (okunye umgcini womntwana) ka- (bhala igama lomntwana ): 
    
Ndinikeza imvume yokujongwa kobume be-HIV emntwaneni wam. 
Isandla somzali okanye umgcini womntwana onikeza imvume: 
  
Igama lomzali okanye umgcini womntwana ngoonobumba abakhulu: 
  
 Umhla:    - 
Isandla sengqinga elingqinisisa imvume:       
 Umhla:      
Igama lengqinga ngoonobumba abakhulu:       
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Appendix 2: 24-Hour-recall 
 
 FOOD ITEMS QUANTITY(g/ml) BR IS L IS D AD 
T
E
A
 &
 C
O
F
F
E
E
 
Tea Cup=180ml; 
mug=250ml 
      
Coffee       
+sugar; syrup; 
honey 
1t sugar=6g; 1t 
honey/syrup=15g 
      
+condensed milk 1t=10g       
+evaporated milk 1t=3g       
+non-dairy 
creamer 
1t=4g       
+WM powder 1t=4g       
+milk: SM; WM; 
2%; soy; breast 
Med portions: 
20ml-tea in cup 
35ml-tea in mug 
40ml-coffee in 
cup 
75ml-coffee in 
mug 
      
Other (specify)        
M
IL
K
 &
 M
IL
K
 D
R
IN
K
S
 
Buttermilk S/s=175ml; 
l/s=500ml; 
½c=125g 
      
Maas/sourmilk       
Custard S/s=350ml       
Milk: SM; WM; 2%; 
soy; breast 
To drink: 
½c=125ml 
Baby 
bottle=250ml 
      
Formula (specify) 
No of scoops/bot 
      
Yoghurt S/s=175ml; 
yogisip=350ml; 
½c=125g 
      
Flavoured milk Carton=250ml; 
s/s plastic=350ml 
      
D
R
IN
K
S
 
Fruit juice-specify Liquifruit 
s/s=250ml; Ceres 
s/s=200ml; 
cartons/bottles 
s/s=350ml, 
l/s=500ml 
      
Cold drinks: 
squash; 
carbonated; diet 
S/s bottle=350ml; 
l/s bottle=500ml; 
s/s can=340ml 
      
B
R
E
A
K
F
A
S
T
 
C
E
R
E
A
L
S
 
Maltabella: soft ½c=125g       
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M/Meal: soft; stiff; 
crumbly 
1 c soft=250g; 1 c 
stiff=250g; 1c 
crumbly=140g 
      
Oats; tastee wheat ½c=125g       
Corn flakes 1c=40g       
Honey crunch; 
muesli 
½c=65g       
Pronutro ½c=50g       
Puffed wheat ½c=12g       
Fruit loops ½c=18g       
Special K; All Bran ½c=25g       
Rice crispies ½c=20g       
Weetbix 1=25g       
+fat: B; HM, Med; 
PM 
1t=5g       
+sugar; syrup; 
honey 
1t sugar=6g; 1t 
honey/syrup=15g 
      
+condensed milk 1t=10g       
+evaporated milk 1t=3g       
+non-dairy 
creamer 
1t=4g       
+WM powder 1t=4g       
+milk: SM; WM; 
2%; soy; breast 
125g-instant 
cereal 
60g-porridge 
180g-pronutro 
      
B
R
E
A
D
 
Bread/rolls: Wh; Br; 
Ww 
Wh+BR 
10mm=30g; Ww 
10mm=35g 
      
Cream crackers; 
Provita; Tuc; 
Crackers Ww 
CrCr=8g; Tuc=4g; 
Provita=6g 
      
Muffins; scones 6cm diam=35g; 
8cm diam=60g 
      
Rusks Comm=15g; other 
30g 
      
S
P
R
E
A
D
S
 O
N
 B
R
E
A
D
 
Butter; Marg: HM 
;med, PM 
Thin=5g; 
Med=7g; 
Thick=10g 
      
Fishpaste; Liver 
spread; meat paste 
Thin=5g; 
Med=7g; 
Thick=10g 
      
Jam; honey; syrup Thin=10g; 
Med=20g; 
Thick=35g 
      
Marmite; meat 
spread 
Thin=2g; 
Med=4g; 
Thick=7g 
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Peanutbutter; 
sandwich spread; 
cheese spread 
Thin=5g; 
Med=10g; 
Thick=20g 
      
 Eggs 1 egg=50g       
C
H
E
E
S
E
 
Cheddar; gouda Grated: 
med=40g; 
cubes=30g; 
slice=8g 
      
Cottage cheese; 
cream cheese 
Med=20g; 
thick=30g 
      
Macaroni cheese 1T=45g; 
1SP=90g; 
½c=115g 
      
M
E
A
T
 
Bacon 1 rasher=10g       
Beef; Bully beef 138x85x3=20g; 
½c=100g 
      
Mince 1T=40g; 
1SP=65g;½c=100
g 
      
Roast 120x60x5=35g       
Steak S/s 
130x70x15=125g; 
L/s 
165x70x20=270g 
      
Stew, vegetables 1SP= 105g; 
½c=125g 
      
Chicken, +skin; 
skin 
Breast=125g; 
thigh=80g; 
drumstick=42g; 
foot=30g; 
wing=30g 
      
Chicken pie Comm.=150g, 
home=90g 
      
Chicken stew 1SP=90g; 
½c=125g 
      
Heart: beef; sheep Sheep heart=50g; 
sheep 
kidney=30g; beef 
kidney=85g 
      
Kidney: beef; 
sheep 
      
Lung: beef       
Lasagne 1T=40g; 
1SP=75g; 
½c=120g 
      
Liver Sheep=55g; 
chicken=30g; 
beef=80g 
      
Mutton chop Louin chop=60g; 
rib chop=40g 
      
Polony Comm slice=16g       
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Pork Chop:115x80x20
=100g 
Roast:110x65x5=
30g 
3 ribs=130g 
      
Samoosa; meat; 
veg 
S/s=42g       
Sausage beef; pork Beef:thinx200mm
=45g; 
thickx165mm=90
g 
Pork med=55g 
      
Spaghetti 
bolognaise 
1T=40g;1SP=75g
; ½c=100g 
      
Toppers/imana, 
cooked 
1SP=85g; 
½c=120g 
      
F
IS
H
 
Fish Small=50x55x30=
60g; med 
100x55x30=120g; 
stew 1SP=95g; 
½c=140g 
      
Fish cakes 65x15mm=50g       
Fish fingers 85mm=35g       
Pilchards 1=75g       
Sardines S/s=7g; l/s=25g       
Tuna 1/3c=50g       
S
T
A
R
C
H
 
M/Meal: soft; stiff; 
crumbly 
Stiff & soft: 
1T=75g; 
1SP=120g; 
½c=125g 
Crum: 1T=30g; 
1SP=75g; 
½c=70g 
      
Samp 1T=55g; 
1SP=125g; 
½c=125g 
      
Rice 1T=25g; 
1SP=60g; 
½c=65g 
      
Pasta (cooked) 1T=35g; 
1SP=70g; 
½c=90g 
      
Spaghetti & tomato 
sauce 
1T=45g; 
1SP=80g; 
½c=125g 
      
Stamped wheat 1T=30g; 
1SP=80g; 
½c=80g 
      
+B; HM; Med; PM; 
SO 
1t=5g       
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S
O
U
P
S
 &
 L
E
G
U
M
E
S
 
Baked beans 1T=50g; 
1SP=105g; 
½c=135g 
      
Beans (cooked) 1T=50g; 
1SP=85g; 
½c=135g 
      
Breyani 1T=40g; 
1SP=80g; 
½c=85g 
      
Lentils (cooked) 1T=40g; 
1SP=80g; 
½c=90g 
      
Samp & beans 1T=50g; 
1SP=125g; 
½c=125g 
      
Soup-packets ½c=125g       
Homemade(specify
) 
1T=35g; 
1SP=80g; 
½c=130g 
      
Sousboontjies 1T=40g; 
1SP=105g; 
½c=135g 
      
Beanstew 1T=60g; 
1SP=120g; 
½c=125g 
      
V
E
G
E
T
A
B
L
E
S
 
Vegetables-Specify        
        
Salad-specify        
        
Potato S/s=60g; 
m/s=90g 
      
Potato mash 1T=50g; 
1SP=115g; 
½c=125g 
      
F R U
I
T
 Fruit-specify        
        
E
X
T
R
A
 
Pudding-specify        
        
Cake+tart-specify        
        
Sweets-specify        
        
IN
F
A
N
T
 F
O
O
D
S
 Baby cereals(dry): 
Nestum1;2;rice& 
maize 
Purity:mixed;w/w;ri
ce 
Cerelac 
1t=2g; 1T=8g; 
½c=20g 
 
      
+sugar; syrup; 
honey 
1t sugar=6g; 1t 
honey/syrup=15g 
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+milk: SM; WM; 
2%; soy; breast 
125g-instant 
cereal 
60g-porridge 
180g-pronutro 
      
First food fruit; veg Jar=80g; 1t=11g       
Fruit juice ½c=125ml       
Infant dinners(dry): 
beef&veg; 
chicken& veg; 
guava& custard; mi 
veg; orange & 
banana 
1t=5g; 1T=15g; 
½c=47g 
      
Junior food(jar): 
veg& meat; mix 
veg; pasta &beef 
Jar=200g; 
1t=11g; ½c=125g 
      
Junior fruit (jar)       
Junior pudding       
Strained food(jar): 
macaroni beef; veg 
&meat; fruit& 
yoghurt; fruit; 
pudding; 
vegetables 
Jar=125g; 
1t=11g; ½c=125g 
      
O
T
H
E
R
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Appendix 3: Food frequency questionnaire 
 
The intake during the past six months by the child and during the past 6 months for babies 
younger than 1 year. 
 
 FOOD DESCRI
PTION 
QUANT
ITY 
(g/ml) 
AMOU
NT 
USUAL
LY 
EATEN 
(HHM) 
AMOU
NT 
USUAL
LY 
EATEN 
(g) P
/D
 
D
/W
 
P
/M
 
S
E
L
D
O
M
/ 
N
E
V
E
R
 
P
O
R
R
ID
G
E
 
Maize-meal 
porridge 
Stiff 1c=250
g 
1T=75g 
      
Soft 1c=250
g 
1T=75g 
      
Crumbly 1c=140
g 
1T=30g 
      
Maltabella 
porridge 
 ½c=125
g 
      
Oats porridge  ½c=125
g 
      
Other cooked 
cereal 
Specify 
type: 
       
Milk on porridge None        
 Full 
cream 
Little= 
30g 
Med= 
60g 
Much= 
125g 
      
 Sour       
 2%       
 Fat free/ 
skim 
      
 Milk 
blend 
      
 Soy milk       
 Condens
ed 
1t= 10g       
 Evaporat
ed 
1t= 3g       
 Non-dairy 
creamer 
1t= 4g       
Is sugar added 
to porridge? 
None        
 White 1t= 6g       
 Brown       
 Syrup 1t= 15g       
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 Honey       
Is fat added to 
porridge? 
None        
 Butter 1t= 5g       
 Hard 
margarin
e 
      
 Soft 
margarin
e (PM) 
      
 Soft 
margarin
e (Med) 
      
 Oil       
 Peanut 
butter 
1t= 12g       
B
R
E
A
K
F
A
S
T
 C
E
R
E
A
L
 
Breakfast 
cereals 
Specify 
types 
usually 
eaten 
       
Baby/ infant 
cereals 
Specify 
type 
usually 
used 
1t= 2g 
1T= 8g 
½c= 
20g 
      
Milk on cereal Specify 
type 
       
Is sugar added 
to cereal? 
Specify 
type 
       
Is fat added to 
cereal 
Specify 
type 
       
S
T
A
R
C
H
E
S
 
Samp  1T= 
55g 
1 SP= 
125g 
½c= 
125g 
      
Samp and 
beans 
Ratio       
Rice White 
Brown 
1T= 
25g; 
1SP= 
60g; ½= 
65g 
      
Stamped wheat  1T= 
30g; 
1SP=80
g; ½c= 
80g 
      
Pasta Macaroni 1T=       
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Spaghetti 35g; 
1SP= 
70g; 
½c= 
90g 
      
Spaghetti 
& tomato 
sauce 
1T= 
45g; 
1SP= 
80g; 
½c=125
g 
      
Do you add fat 
to these starchy 
foods? 
Yes   No 
If yes, 
specify 
       
B
R
E
A
D
S
 &
 S
P
R
E
A
D
S
 
Bread/ bread 
rolls 
White 10mm=
30g; 
20mm= 
60g; 
30mm= 
400g; ½ 
loaf= 
400g 
      
 Brown       
 Wholewh
eat 
10mm= 
35g 
      
 Other        
Crackers Provita 6g       
Cream 
crackers 
8g       
Refined 4g       
Wholewh
eat 
8g       
Are any of the 
following 
spreads on the 
child‟s bread? 
Butter 1t= 5g       
Lard       
Hard 
margarin
e 
      
Soft 
margarin
e (PM) 
      
Soft 
margarin
e (Med) 
      
Peanutbutter  1t= 12g       
Sweet spreads Jam  1t= 15g       
Syrup       
Honey       
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Marmite/ oxo  Thin= 
2g; 
med= 
4g; 
thick= 
7g 
      
Paste Fish 
paste 
Thin= 
5g; 
med= 
7g; 
thick= 
10g 
      
 Meat 
paste 
      
Cheese Cheddar Grated: 
med= 
10g; 
thick= 
15g; 
cube= 
8g 
      
 Gouda       
 Cottage Med= 
20g; 
thick= 
30g 
Thin= 
10g 
      
 Cream 
cheese 
      
Cheese spread  Med= 
12g; 
thick= 
25g 
      
Atchar  1T=14g
; 1SP= 
60g 
      
C
H
IC
K
E
N
 
Chicken Boiled 
with skin 
Breast= 
125g 
Thigh= 
80g 
Drumsti
ck= 42g 
Foot= 
30g 
Wing= 
30g 
      
 Boiled 
without 
skin 
      
 Fried in 
batter/ 
crumbs 
      
 Fried, not 
coated 
      
 Grilled, 
with skin 
      
 Grilled, 
without 
skin 
      
Chicken stew With 
vegetable
s 
1SP= 
90g 
½c= 
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 With tom 
& onion 
125g       
Chicken offal Giblets Stomac
h= 20g 
      
Chicken liver  Liver= 
30g 
      
Chicken pie Comm./ 
homema
de 
Med= 
150g 
      
R
E
D
 M
E
A
T
 
Beef Roasted 
with fat 
120x60
x5=35g 
120x60
x10=70
g 
 
      
 Roasted, 
fat 
trimmed 
      
 Rump, 
fried with 
fat 
S/s 
130x70
x15=12
5g 
L/s 
165x70
x30=27
0g 
      
 Rump, 
fried 
without 
fat 
      
 Stewed 
with fat 
(vegetabl
es) 
1SP=10
5g; 
½c=125
g 
      
 Stewed 
without 
fat 
(vegetabl
es) 
      
 Mince 1T=40g
; 
1SP=85
g; 
½c=100
g 
      
Mutton Grilled, 
with fat 
Loin 
chop=6
0g 
Rib 
chop=4
0g 
      
 Grilled, 
without 
fat 
      
 Stew 1SP=10
5g 
½c=125
      
 Stew, 
vegetable 
      
 Stew, 
curry 
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 Stew, 
greenbea
n 
g       
Pork Grilled, 
with fat 
Chop:1
15x80x
20=100
g 
Roast:1
10x65x
5=30g 
1SP=10
5g 
½c=125
g 
      
 Grilled, 
without 
fat 
      
 Roast, 
with fat 
      
 Roast, 
without 
fat 
      
M
E
A
T
: 
G
E
N
E
R
A
L
 
Offal Liver:beef 80g       
 Liver: 
sheep 
55g       
 Kidney: 
beef 
85g       
 Kidney: 
sheep 
30g       
 Tripe, 
beef 
1SP=10
5g; 
½c=125
g 
      
 Heart, 
beef 
60g       
 Heart, 
sheep 
60g       
 Lung, 
beef 
60g       
Wors Thin 200mm
=45g 
      
 Thick 165mm
=90g 
      
Bacon Fat 1 
rasher=
10g 
      
 Lean       
Cold meats Polony Sliced 
5mm 
thick=8
g; 
Comm 
slice=1
6g 
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 Ham Med 
slice=2
5g 
      
 Viennas 100mm
=30g; 
150mm
=40g 
      
Canned meat Bully beef 138x85
x3= 
20g; 
½c=100
g 
      
 Other        
Meat pie Comm 120g       
Legumes Stews 
(Bean,pot
ato & 
onion) 
1T=60g
; 
1SP=12
0g; 
½c=125
g 
      
Soups: 
Split pea 
Lentil 
Beef & 
vegetable 
Bean 
½c=130
g; 
1SP=80
g;1T=3
5g 
      
Legume 
salad 
1T=40g
; 
1SP=10
5g; 
½c=135
g 
      
Soya products Specify 1SP= 
85g; 
½c= 
120g 
      
F
IS
H
 
Fried fish With 
batter 
Small 
50x55x
30mm=
60g 
Med 
100x55
x30mm
=120g 
      
 Without 
batter 
      
Canned fish Pilchards 
in tom 
sauce 
1 
pilchard
= 75g 
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 Pilchards, 
mashed 
1SP=85
g; 
½c=100
g 
      
 Sardines 
in oil 
Small=7
g; 
Large=
25g 
      
 Sardines 
in tom 
sauce 
      
 Tuna in 
oil 
½c=50g       
 Tuna in 
brine 
      
Pickled/ curried 
fish 
 1SP=95
g; 
½c=140
g 
      
Fish cakes Fried 65x15m
m=50g 
      
Fish fingers Fried 85mm=
35g 
      
Shellfish Specify        
E
G
G
S
 Eggs Fried 1 whole 
egg 
      
Scramble
d 
      
Boiled       
C
H
E
E
S
E
 
Hard cheese  Grated: 
med 
40g; 1 
slice=8
g; 
cubes=
30g 
      
Macaroni 
cheese 
 1T=45g
; 
1SP=90
g; 
½c=115
g 
      
Cottage cheese; 
cream cheese 
        
V
E
G
E
T
A
B
L
E
S
 
Cabbage Boiled 1T=30g
; 
1SP=55
g; 
½c=80g 
      
Fried       
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Spinach/Marog Boiled, 
nothing 
added 
1T=40g
; 
1SP=10
5g;½c=
90g 
      
Boiled 
with 
potato & 
onion 
1T=50g
; 
1SP=10
5g;½c=
110g 
      
Tomato & onion Homema
de 
1T=35g
; 
1SP=75
g; 
½c=140
g 
      
 Canned       
Pumpkin, 
specify type 
Boiled 1T=45g
; 
1SP=85
g; 
½c=105
g 
      
 Cooked 
with fat & 
sugar 
      
Carrots Boiled, 
sugar & 
fat 
1T=25g
; 
1SP=50
g; 
½c=85g 
      
 With 
potato & 
onion 
1T=35g
; 
1SP=70
g; 
½c=105
g 
      
 Raw, 
salad 
1T=25g       
Mealies On cob 1T=30g
; 
1SP=60
g; 
½c=95g 
      
Creamed, 
sweet 
corn 
1T=55g
; 
1SP=12
5g; 
½g=135
g 
      
Whole 
kernel 
corn 
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Beetroot Cooked 1T=40g
; 
1SP=70
g; 
½c=80g 
      
Salad 1T=25g
; 
1SP=65
g 
      
Potatoes Boiled Small=6
0g; 
med=90
g 
      
Mashed 1T=50g
; 
1SP=11
5g; 
½c=125
g 
      
Roasted 1 
med=70
g 
      
French 
fries 
½c=50g
; 
med=80
g 
      
Salad 1T=45g
; 
1SP=10
5g; 
½c=120
g 
      
Sweet potato Boiled 1T=50g
; 
1SP=11
0g; 
½c=145
g 
      
Mashed       
Green beans Boiled 1T=30g
; 
1SP=65
g; 
½c=90g 
      
Cooked, 
potato & 
onion 
1T=40g
; 
1SP=75
g; 
½c=120
g 
      
Peas Cooked ½c=85g       
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Green pepper         
Mushrooms  1T=30g
; 
1SP=65
g; 
½c=80g 
      
Onions  1T=50g       
Salad 
vegetables 
Raw 
tomato 
Med=12
0g; 
Slice=1
5g 
      
Lettuce 1 
leaf=30
g 
      
Cucumbe
r 
Medslic
e=10g; 
thick=1
5g 
      
Avocado ¼avo 
(80x50
mm)=4
0g 
      
Vegetable 
purees for 
babies or infants 
(specify) 
First food 
vegetable 
(jar) 
1t=5g; 
1T=15g
; 
½c=47g 
      
Junior 
food veg 
(jar) 
      
Junior 
food veg 
plus meat 
      
Other       
D
R
E
S
S
IN
G
S
 Mayonnaise/ 
salad dressing 
Mayonnai
se 
1t=10g; 
1T=40g 
      
Salad 
dressing, 
French 
1t=5g; 
1T=15g 
      
Oil 1t=5g; 
1T=15g 
      
F
R
U
IT
 
Apples  1 
med=15
0g 
      
Bananas  1 
med=75
g 
      
Oranges/naartji
es 
 Med=18
0g 
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Grapes  Med 
bunch=
230g; 
½c=90g 
      
Peaches  Med=15
0g 
      
Apricots  Med=35
g 
      
Mangoes  135mm
= 350g 
      
Pawpaw  Wedge 
165x26
x27mm
=90g 
      
Pineapple  1 
slice=4
0g 
      
Guavas  Med=95
g 
      
Pears  Med=16
5g 
      
Dried fruit Raisins 1 
handful 
=27g 
      
Prunes 1T=50g
; 
½c=110
g; 
1=12g 
      
Peaches Med=15
0g 
      
Apples 1T=60g
; 
½c=120
g 
      
Dried fruit 
sweets 
       
Fruit purees for 
babies/ infants 
First food 
(jar) 
Jar=200
g 
1t=11g 
½c=125
g 
      
Junior 
fruit (jar) 
      
Other       
D
R
IN
K
S
 
Milk Whole ½c=125
ml 
Baby 
bottle= 
250ml 
      
2%       
Fat free       
Sour       
Infant 
formula, 
specify 
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Milk drinks Drinking 
chocolate 
1t=5g       
Malted 
milk 
beverage 
1t=5g       
Flavoure
d milk 
Carton=
250ml; 
small 
plastic=
350ml 
      
Yoghurt Drinking Small=1
75ml; 
Yogisip
=350ml; 
½c=125
g 
      
Thick: fat 
free; 
Low fat 
      
Squash 
(specify) 
 S/s 
glass= 
150ml; 
med=25
0ml 
large=5
00ml; 
small 
bottle=3
50ml, 
large=5
00ml; 
small 
can 
350ml 
      
Fruit juice Specify        
Fizzy drinks Sweeten
ed 
S/s 
Bottle=
350ml; 
L/s 
Bottle=
500ml; 
s/s 
can=34
0ml 
      
 Diet       
S
N
A
C
K
S
 
Potato crisps         
Peanuts         
Cheese curls         
Popcorn         
Chocolates         
Sweets Specify        
Biscuits/cookies Specify        
Cakes/tarts Specify        
Rusks         
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Scones  6cm 
diam=3
5g; 8cm 
diam=6
0g 
      
Muffins        
Koeksisters  100x35
=60g 
      
Savouries Sausage 
rolls 
135mm
=165g 
      
 Samoosa
s 
S/s=42
g 
      
 Biscuits 4g       
P
U
D
D
IN
G
S
 
Jelly  1T=35g
; 
1SP=75
g; 
½c=110
g 
      
Baked pudding Specify Med 
serv=30
g; 
30x65x
65=50g 
      
Instant pudding Specify 1T=45g
; 
1SP=95
g; 
½c=145
g 
      
Infant desserts Specify Jar=200
g; 
1t=11g; 
½c=125
g 
      
Ice cream Specify Scoop=
40g; 
1SP=65
g; 
½c=75g 
      
Custard  1T=13g
; 
1SP=40
g 
      
 
 
Are there any foods that the child eats which we haven‟t talked about? 
Foods Description Amount 
usually 
eaten 
Times eaten  
   Per Per Per Seldo  
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day week month m 
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Appendix 4: Immunologic categories for HIV-infected children based on age-specific 
CD4 T-lymphocyte count 
 
Immunologic catagory Cells/µl 
<12 months 1-5 years 6-12 years 
No evidence of 
suppression 
≥1 500 ≥1 000 ≥500 
Evidence of moderate 
suppression 
750 – 1 499 500 - 999 200 - 499 
Severe suppression <750 <500 <200 
From: MMWR Vol. 46/ No. RR 1283 
 
